NIR-II Fluorescence Imaging in Surgery: A Complete Guide to Probe Development and Clinical Translation

Abstract

This comprehensive review explores the rapidly advancing field of second near-infrared (NIR-II, 1000-1700 nm) fluorescent probes for image-guided tumor surgery. We first establish the foundational principles of NIR-II imaging, explaining its superior advantages over traditional NIR-I and visible-light imaging in terms of penetration depth, resolution, and signal-to-background ratio. We then delve into the methodological design of molecular, nanoparticle, and targeted NIR-II probes, alongside their specific intraoperative applications for tumor margin delineation, lymph node mapping, and nerve preservation. Critical troubleshooting and optimization strategies for improving probe brightness, stability, biocompatibility, and clearance are systematically addressed. Finally, we provide a rigorous validation and comparative analysis of leading probe platforms against clinical standards and emerging alternatives. This article serves as an essential resource for researchers and drug development professionals navigating the path from probe design to preclinical validation and ultimate clinical implementation.

NIR-II Fluorescence Fundamentals: Why 1000-1700 nm is Revolutionizing Surgical Vision

Within the broader thesis on developing NIR-II fluorescent probes for image-guided tumor surgery, a precise understanding of the NIR-II optical window is foundational. This region, typically defined as 1000-1700 nm, offers superior imaging depth and resolution compared to the traditional NIR-I (700-900 nm) window. This advantage stems from fundamental physical reductions in photon scattering and tissue autofluorescence, alongside minimized absorption by major tissue chromophores like water and hemoglobin. These Application Notes detail the optical properties defining this window and provide protocols for their empirical validation, which is critical for optimizing probe design and intraoperative imaging systems.

Optical Properties: Quantitative Data

The superior performance of the NIR-II window is quantitatively demonstrated by the reduced absorption and scattering coefficients of biological tissues.

Table 1: Absorption Coefficients (μₐ) of Key Tissue Chromophores Across Spectral Windows

Chromophore	μₐ at 800 nm (NIR-I) [cm⁻¹]	μₐ at 1300 nm (NIR-IIa) [cm⁻¹]	Reduction Factor
Oxy-Hemoglobin (HbO₂)	~0.4	~0.02	20x
Deoxy-Hemoglobin (HbR)	~1.5	~0.05	30x
Water (H₂O)	~0.02	~0.4	(Increase)
Lipid	~0.1	~0.3	(Increase)

Note: Water absorption increases significantly beyond ~1350 nm, defining the practical long-wavelength boundary of the NIR-II window for deep tissue imaging.

Table 2: Reduced Scattering Coefficients (μₛ') in Biological Tissue

Tissue Type	μₛ' at 800 nm [cm⁻¹]	μₛ' at 1300 nm [cm⁻¹]	Approximate Reduction
Brain (Gray Matter)	~12	~6	2x
Skin (Dermis)	~18	~8	2.25x
Breast Tissue	~10	~5	2x
Muscle	~14	~7	2x

The reduction in scattering follows an approximate λ^(-γ) dependence, where γ typically ranges from 0.5 to 2 for biological tissues.

Experimental Protocols

Protocol 1: Measuring Bulk Optical Properties of Ex Vivo Tissue Using an Integrating Sphere Objective: Quantify the absorption (μₐ) and reduced scattering (μₛ') coefficients of tissue samples.

• Sample Preparation: Prepare thin, uniform slices (e.g., 1 mm thickness) of fresh or properly preserved ex vivo tissue (e.g., mouse liver, tumor, muscle) using a vibratome.
• System Setup: Use a dual-integrating sphere system (reflectance and transmission spheres) coupled to a tunable NIR laser source (1000-1600 nm) and a calibrated NIR-II detector (e.g., InGaAs photodiode).
• Measurement: Place the tissue sample at the sample port between the two spheres. For each wavelength, measure the total diffuse reflectance (Rₜ) and total transmittance (Tₜ).
• Data Analysis: Employ an inverse adding-doubling (IAD) algorithm. Input Rₜ, Tₜ, sample thickness, and the refractive index mismatch into the algorithm to solve for μₐ and μₛ'.
• Validation: Verify results using phantoms with known optical properties (e.g., Intralipid for scattering, India ink for absorption).

Protocol 2: In Vivo Determination of Photon Mean Free Path via Trans-cranial Imaging Objective: Demonstrate increased imaging depth in the NIR-II window by measuring the attenuation of signal through increasing tissue thickness.

• Animal Model: Use a nude mouse skull or prepare a mouse with a thinned-skull cranial window.
• Probe Administration: Systemically administer a bright, stable NIR-II fluorophore (e.g., IRDye 800CW for NIR-I control, IR-1061 for NIR-II) via tail vein injection.
• Imaging Setup: Use a NIR-II fluorescence imaging system with separate 808 nm and 1064 nm laser excitation paths and a cooled InGaAs camera.
• Data Acquisition: Acquire fluorescence images through the intact skull at both NIR-I and NIR-II excitation/emission windows. Use identical laser power and integration times.
• Quantification: Measure the signal-to-background ratio (SBR) and the full-width at half-maximum (FWHM) of visible vasculature in both channels. The NIR-II channel will show higher SBR and lower FWHM, indicating less scattering and greater clarity.

Visualization: Physics and Workflow

Diagram Title: Photon-Tissue Interaction Benefits in NIR-II Window

Diagram Title: Experimental Workflow for NIR-II Validation

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Optical Property Studies

Item	Function & Explanation
Tunable NIR Laser Source (1000-1700 nm)	Provides precise wavelength selection for measuring wavelength-dependent absorption and scattering coefficients.
Cooled InGaAs Camera (SWIR Camera)	The standard detector for NIR-II light, sensitive from ~900-1700 nm. Cooling reduces dark noise.
Integrating Sphere Setup (Dual Sphere)	Essential for measuring total reflectance/transmittance of tissue samples to extract μₐ and μₛ' via IAD algorithms.
NIR-II Fluorescent Probes (e.g., IR-1061, PbS Quantum Dots, CH-4T)	Bright, photostable emitters in the NIR-II window used as contrast agents in phantom and in vivo validation experiments.
Tissue-Simulating Phantoms (Intralipid & India Ink)	Calibration standards. Intralipid provides controlled scattering, while India ink provides controlled absorption.
Inverse Adding-Doubling (IAD) Software	Computational tool required to calculate the intrinsic optical properties (μₐ, μₛ') from integrating sphere measurement data.

Near-infrared window II (NIR-II, 1000-1700 nm) fluorescence imaging has emerged as a transformative modality for image-guided surgery, offering profound advantages over traditional NIR-I (700-900 nm) techniques. Within the context of developing novel NIR-II fluorescent probes for tumor surgery, quantifying these advantages is critical. This application note provides a detailed comparison and standardized protocols to empirically validate the superior tissue penetration depth and spatial resolution of NIR-II imaging.

Quantitative Comparison: NIR-I vs. NIR-II

Table 1: Comparative Optical Properties in Biological Tissue

Parameter	NIR-I (750-900 nm)	NIR-II (1000-1700 nm)	Measurement Method
Scattering Coefficient (μs')	~0.7-1.0 mm⁻¹	~0.3-0.5 mm⁻¹	Inverse Adding-Doubling on ex vivo tissue slabs.
Autofluorescence	High (from lipids, collagen)	Negligible	Spectroscopy of tissue phantoms & in vivo models.
Photons Reaching Detector	~0.1% at 4 mm depth	~1-2% at 4 mm depth	Monte Carlo simulation & phantom validation.
Theoretical Resolution Limit	~20-30 μm at 3 mm depth	~10-15 μm at 3 mm depth	Modulation Transfer Function (MTF) analysis.
Typical In Vivo Resolution	150-300 μm	25-50 μm	Measured via subcutaneously implanted capillary tubes.
Maximum Useful Penetration	5-8 mm	15-20 mm	Signal-to-Background Ratio (SBR) > 2.0 threshold.

Table 2: Performance Metrics in Murine Tumor Surgery Models

Metric	NIR-I Probe (e.g., ICG)	NIR-II Probe (e.g., CH1055)	Experimental Setup
Tumor-to-Background Ratio (TBR)	2.5 ± 0.5	8.5 ± 1.2	IV injection, imaging at 24h post-injection.
Signal-to-Noise Ratio (SNR) at 5mm	8.2 ± 2.1	42.7 ± 5.8	Probe embedded in tissue-mimicking phantom.
Detection of Sub-mm Satellites	≤ 500 μm	≤ 100 μm	Orthotopic glioma model with micro-metastases.
Real-time Imaging Frame Rate	10-15 fps	20-50 fps	Limited by camera sensitivity & laser power.
Vessel Resolution	~200 μm diameter	~30 μm diameter	Cerebral vasculature imaging through skull.

Detailed Experimental Protocols

Protocol 1: Quantifying Penetration Depth in Tissue Phantoms

Objective: To measure and compare the attenuation of NIR-I and NIR-II fluorescence signals through varying thicknesses of biological tissue.

Materials:

• NIR-I dye (e.g., Indocyanine Green, IRDye 800CW)
• NIR-II dye (e.g., IR-1061, CH1055-PEG)
• Tissue-mimicking phantom (1% Intralipid in agarose, or ex vivo chicken breast)
• NIR-I Imaging System (e.g., LI-COR Pearl, 785 nm excitation, 820 nm LP emission filter)
• NIR-II Imaging System (e.g., InGaAs camera, 1064 nm laser, 1300 nm LP emission filter)
• Calibrated thickness spacers (0.5 mm to 20 mm)

Procedure:

• Prepare dye solutions at identical molar concentrations (e.g., 100 µM) in PBS.
• Place a 50 µL droplet of dye solution on the imaging stage.
• Cover the droplet with the tissue phantom slab of initial thickness (e.g., 0.5 mm).
• Acquire fluorescence images with both NIR-I and NIR-II systems using identical integration times and laser power densities (e.g., 100 ms, 50 mW/cm²).
• Quantify the mean fluorescence intensity (MFI) within a defined ROI over the droplet location.
• Repeat steps 3-5, incrementally increasing phantom thickness up to 20 mm.
• Normalize all MFI values to the signal obtained with no phantom (0 mm thickness).
• Plot normalized intensity vs. thickness. Fit curves with the modified Beer-Lambert law: I = I₀ * exp(-μeff * d), where μeff is the effective attenuation coefficient.

Analysis: The NIR-II signal will exhibit a significantly lower μeff, confirming deeper penetration. The useful depth is defined as the thickness where SNR drops below 3.

Protocol 2: Measuring Spatial Resolution In Vivo

Objective: To determine the practical spatial resolution for distinguishing fine anatomical features in living subjects.

Materials:

• NIR-II fluorescent probe (targeted or non-targeted).
• Anesthetized mouse model (e.g., orthotopic tumor or transgenic).
• High-sensitivity NIR-II imaging system with precise focusing.
• Calibration target (USAF 1951 resolution chart modified with NIR-II dye).

Procedure:

• System Calibration: Image the NIR-II-dyed resolution chart to determine the system's in-air resolution limit (typically 5-20 µm).
• Animal Preparation: Administer the NIR-II probe intravenously to the mouse. Allow appropriate circulation time (e.g., 24h for targeted probes).
• Superficial Vasculature Imaging: Image an area with fine vasculature (e.g., ear or hindlimb). Use the shortest possible exposure time without saturating the camera.
• Deep Tissue Challenge: Surgically implant a thin capillary tube (inner diameter ~100 µm) filled with NIR-II dye at a defined depth (e.g., 3-5 mm) beneath a muscle flap. Suture the incision.
• Acquire high-resolution images of the implantation site.
• Data Processing: For the capillary tube image, plot the fluorescence intensity profile across the tube's width (line profile). Apply a Gaussian fit. The spatial resolution is defined as the Full Width at Half Maximum (FWHM) of this fitted peak.
• Compare the measured FWHM in vivo to the in-air calibration. The degradation is primarily due to tissue scattering.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Tumor Surgery Research

Item	Function & Rationale
NIR-II Fluorophores (e.g., CH1055, IR-FEP, LZ-1105)	Core imaging agent. Organic small molecules offering brightness, biocompatibility, and often renal clearance.
Targeted Conjugates (e.g., EGFR-Affibody-CH1055)	For specific tumor delineation. A targeting moiety (antibody, peptide) linked to a NIR-II dye enhances TBR.
Commercial NIR-II Dyes (e.g., IR-1061, FD-1080)	Benchmarks and controls for probe development and protocol standardization.
Tissue-Mimicking Phantoms (Intralipid/Agarose)	To simulate optical scattering and absorption properties of tissue for reproducible in vitro penetration tests.
InGaAs Camera (Cooled, 512x512 pixel)	Essential detector for NIR-II light. High quantum efficiency in 1000-1700 nm range. Requires cooling to reduce dark noise.
1064 nm Diode Laser	Common excitation source for NIR-II fluorophores. Must be equipped with appropriate filters and beam shaping optics.
Long-pass Emission Filters (>1200 nm, 1300 nm, 1500 nm)	Critical for blocking excitation laser light and NIR-I autofluorescence, isolating pure NIR-II signal.
Stereotactic Surgical Platform	For precise orthotopic tumor implantation and reproducible surgical models in small animals.
Image Analysis Software (e.g., ImageJ with NIR-II plugins)	For quantitative analysis of intensity, TBR, SNR, and resolution (FWHM calculations).

Visualizations

NIR-I vs NIR-II Light-Tissue Interaction

Protocol: Penetration Depth Measurement Workflow

NIR-II Guided Surgical Decision Logic

Within the thesis on developing next-generation NIR-II fluorescent probes for image-guided tumor surgery, maximizing the Signal-to-Background Ratio (SBR) is the paramount objective. High autofluorescence from biological tissues (e.g., collagen, elastin, flavins) in the traditional NIR-I window (700-900 nm) severely limits tumor contrast. The NIR-II window (1000-1700 nm) offers intrinsically reduced photon scattering and minimal autofluorescence. This application note details protocols and strategies to quantify, minimize, and leverage this SBR advantage for superior intraoperative visualization.

Quantifying the SBR Advantage: NIR-I vs. NIR-II

The following table summarizes key comparative metrics from recent seminal studies, highlighting the quantitative SBR improvement in the NIR-II region.

Table 1: Quantitative Comparison of SBR Performance: NIR-I vs. NIR-II Probes In Vivo

Probe / Platform	Emission Max (nm)	Tumor Model	Key Comparative Metric (NIR-II vs. NIR-I)	Reported SBR (or TBR)	Reference (Year)
CH1055-PEG	~1055	U87MG Glioblastoma	Signal-to-Background Ratio (SBR)	SBR_NIR-II: ~3.5	Nature Biomed Eng (2017)
IRDye 800CW	~800	(Same tumor, same mouse)	Signal-to-Background Ratio (SBR)	SBR_NIR-I: ~2.0
LZ1105	~1060	4T1 Breast Cancer	Tumor-to-Background Ratio (TBR)	TBR > 8.0 @ 24h p.i.	Nature Mater (2019)
Commercial NIR-I Dye	~800	(Comparative control)	Tumor-to-Background Ratio (TBR)	TBR ~ 3.0
Ag2S Quantum Dots	~1200	CT26 Colon Carcinoma	Spatial Resolution (FWHM)	~36 µm (through skull)	Nature Photon (2014)
			(NIR-I counterpart)	> 100 µm

Core Experimental Protocols

Protocol 1:In VivoSBR/TBR Quantification for Probe Evaluation

Objective: To quantitatively compare the tumor-targeting efficiency and background suppression of NIR-II probes. Materials: NIR-II fluorescent probe, NIR-II imaging system (e.g., InGaAs camera with 1064 nm laser), mouse tumor xenograft model, anesthetic (isoflurane), heating pad. Procedure:

• Probe Administration: Inoculate mice with subcutaneous or orthotopic tumors. Upon reaching ~100-300 mm³, inject probe intravenously (dose: 1-5 nmol in 100-200 µL PBS).
• Image Acquisition: Anesthetize mouse and place prone on heated stage. Acquire time-series images at defined post-injection (p.i.) intervals (e.g., 1, 4, 24, 48 h).
  • Settings: Use 1064 nm excitation (power density: 10-100 mW/cm²). Apply appropriate long-pass filters (e.g., LP1250 nm). Set exposure time (100-500 ms) to avoid saturation.
• Region of Interest (ROI) Analysis:
  • Using imaging software, draw ROIs over the entire tumor (T) and adjacent normal background tissue (B) of identical area.
  • Record the mean fluorescence intensity (MFI) for each ROI.
• Calculation: Compute SBR for each time point: SBR = MFITumor / MFIBackground. Tumor-to-Background Ratio (TBR) is synonymous.

Protocol 2: Ex Vivo Biodistribution for Specificity Validation

Objective: To confirm probe accumulation in tumor vs. major organs, verifying SBR at the tissue level. Materials: Dissection tools, pre-weighed microcentrifuge tubes, tissue homogenizer, NIR-II imaging system or plate reader. Procedure:

• Tissue Harvest: At peak SBR time point (e.g., 24 h p.i.), euthanize mouse. Perfuse with PBS via cardiac puncture. Excise tumor, heart, liver, spleen, lungs, kidneys, muscle, and skin.
• Imaging & Weighing: Image all tissues ex vivo under the NIR-II system. Precisely weigh each tissue.
• Fluorescence Quantification:
  • Homogenize each tissue in PBS (e.g., 1 mL per 100 mg).
  • Centrifuge homogenates (12,000 rpm, 10 min).
  • Measure fluorescence of supernatant in a NIR-II-compatible plate reader or against a standard curve.
• Data Expression: Calculate %ID/g (percentage of injected dose per gram of tissue). High tumor %ID/g and low background organ %ID/g correlate with high SBR.

Visualization of Key Concepts

Diagram Title: The NIR-II Advantage for High SBR

Diagram Title: NIR-II Probe Evaluation Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for NIR-II SBR Optimization Research

Item / Reagent	Function & Relevance to SBR
NIR-II Fluorescent Probes (e.g., CH1055 derivatives, LZ1105, Ag2S/Ag2Se QDs, Dye-Dye Conjugates)	Core imaging agent. Engineered for high quantum yield, target affinity (e.g., to integrins, EGFR), and optimal excretion kinetics to maximize tumor signal and minimize background.
IRDye 800CW	Benchmark NIR-I dye for direct comparative SBR studies under identical conditions.
Anti-EGF Receptor or αvβ3-Integrin Targeting Ligands (Peptides, Antibodies, Affibodies)	Conjugated to NIR-II probes to achieve active tumor targeting, enhancing specific signal accumulation.
PEGylation Reagents (e.g., mPEG-NHS)	Used to modify probe hydrophilicity and size, prolonging circulation time and reducing non-specific uptake (lowering background).
Matrigel	For establishing consistent subcutaneous tumor xenografts in mice.
Isoflurane Anesthesia System	Ensures stable, motion-free imaging for accurate SBR quantification over time.
NIR-II Imaging System (InGaAs camera, 1064/808 nm lasers, LP filters)	Essential hardware. Camera sensitivity and laser power directly impact detectable signal and background noise floor.
IVIS Spectrum or MICS (with NIR-II capabilities)	Standardized commercial platform for longitudinal, quantitative in vivo SBR tracking.
Image Analysis Software (e.g., Living Image, ImageJ)	For precise ROI analysis to calculate MFI and derive SBR/TBR values.

Within the broader thesis on NIR-II fluorescent probes for image-guided tumor surgery, this application note delineates the pivotal transition from the serendipitous use of the first NIR-I dye, Indocyanine Green (ICG), to the rational design of molecularly targeted NIR-II agents. This evolution is driven by the need for deeper tissue penetration, higher spatial resolution, and specific biomarker delineation for intraoperative decision-making.

Quantitative Comparison: ICG vs. Purpose-Built NIR-II Probes

Table 1: Key Optical and Functional Properties

Property	Indocyanine Green (ICG)	Purpose-Built NIR-II Probes (e.g., CH1055-PEG)
Emission Peak (nm)	~820-850 nm (NIR-I)	1000-1700 nm (NIR-II)
Tissue Penetration Depth	1-3 mm	5-10 mm
Spatial Resolution	Limited by scattering	Significantly enhanced (e.g., ~25 µm at 3mm depth)
Signal-to-Background Ratio (SBR)	Moderate (~2-3)	High (>5-10)
Targeting Mechanism	Passive accumulation (EPR) & nonspecific	Active targeting (e.g., anti-EGFR, Integrin αvβ3)
Molecular Weight (Da)	~775	Typically > 20,000 (conjugates)
Ex/Em Filters (Example)	Ex: 780/20 nm, Em: 845/55 nm	Ex: 808 nm LP, Em: 1000 nm LP or 1000-1400 nm bandpass

Table 2: In Vivo Performance Metrics in Murine Tumor Models

Metric	ICG (Passive)	NIR-II Small Molecule Dye (Passive)	Targeted NIR-II Nanoprobe
Time to Peak Tumor Signal	1-4 hours post-injection	2-6 hours post-injection	6-24 hours post-injection
Tumor-to-Background Ratio (TBR)	~1.8 ± 0.3	~3.5 ± 0.5	>8.0 ± 1.2
Blood Half-life (t1/2)	2-4 minutes	0.5-2 hours (PEGylated)	4-24 hours (nanoparticle)
Primary Clearance Route	Hepatobiliary	Hepatobiliary/Renal (tunable)	Reticuloendothelial System (RES)/Hepatobiliary

Experimental Protocols

Protocol 1: Comparative In Vivo NIR-I vs. NIR-II Imaging of Tumor Vasculature using ICG

• Objective: To demonstrate the superior resolution of NIR-II imaging over NIR-I using the same dye (ICG).
• Materials: Nude mouse with subcutaneous tumor, ICG solution (1 mg/mL in saline), NIR-I imaging system, NIR-II imaging system with InGaAs camera.
• Procedure:
  • Anesthetize the mouse and place it on a heated imaging stage.
  • Acquire a pre-contrast background image in both NIR-I and NIR-II channels.
  • Intravenously inject 100 µL of ICG solution via the tail vein.
  • Immediately initiate dynamic imaging for 5 minutes (1 frame/sec) in both channels simultaneously or sequentially.
  • Image Processing: For each channel, quantify signal intensity in a major tumor vessel and adjacent tissue. Calculate contrast-to-noise ratio (CNR) = (Signalvessel - Signaltissue) / SD_background.
• Key Analysis: Overlay early time-point images to show vessel clarity. Plot time-intensity curves and compare CNR values between NIR-I and NIR-II windows.

Protocol 2: Synthesis and Purification of a Targeted NIR-II Probe (e.g., anti-EGFR-CH1055 Conjugate)

• Objective: To prepare a monoclonal antibody-conjugated NIR-II probe for specific tumor targeting.
• Materials: CH1055-PEG-NHS ester dye, anti-EGFR antibody (cetuximab), sodium bicarbonate buffer (0.1 M, pH 8.5), Zeba Spin Desalting Column (7K MWCO), PD-10 desalting column.
• Procedure:
  • Antibody Preparation: Dialyze 1 mg of anti-EGFR antibody into bicarbonate buffer to remove amines.
  • Conjugation: Add a 5-10 molar excess of CH1055-PEG-NHS ester in DMSO to the antibody solution. React for 2 hours at room temperature in the dark with gentle agitation.
  • Purification: Pass the reaction mixture through a Zeba column pre-equilibrated with PBS to remove unreacted dye. Alternatively, use size-exclusion chromatography (PD-10 column).
  • Characterization: Determine the degree of labeling (DOL) by measuring absorbance at 280 nm (protein) and the dye's peak (e.g., 750 nm for CH1055). Confirm integrity via SDS-PAGE with NIR-II fluorescence scanning.
• Key Analysis: Calculate DOL. Validate binding specificity via in vitro cell staining with EGFR+ and EGFR- cell lines.

Protocol 3: Intraoperative Simulation for Tumor Margin Delineation

• Objective: To evaluate a targeted NIR-II probe for defining tumor margins during simulated surgery.
• Materials: Orthotopic or subcutaneous tumor mouse model, targeted NIR-II probe, NIR-II fluorescence imaging system, surgical tools.
• Procedure:
  • Inject the probe intravenously 24 hours prior to imaging.
  • Anesthetize the mouse and perform a surgical exposure of the tumor area.
  • Acquire white-light and NIR-II fluorescence images of the exposed surgical field.
  • Simulated Resection: Use real-time NIR-II guidance to resect the fluorescent core. Subsequently, image the resection cavity to identify any residual fluorescent foci.
  • Resect any residual fluorescent tissue.
  • Perform histopathological analysis (H&E) of the resected pieces to correlate fluorescence with viable tumor cells.
• Key Analysis: Quantify SBR of primary tumor and residual foci. Calculate sensitivity and specificity of NIR-II fluorescence for detecting tumor-positive margins via correlation with histology.

Diagrams

Title: Evolution from ICG to NIR-II Probe Applications

Title: Workflow for NIR-II Guided Surgery

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Probe Development & Imaging

Item	Function & Rationale
ICG (Indocyanine Green)	First-in-class NIR-I fluorophore; benchmark for performance comparison and vascular imaging studies.
NIR-II Organic Dyes (e.g., CH1055, IR-1061)	Core fluorescent molecules with emissions >1000 nm; building blocks for probe construction.
PEG Linkers (NHS-PEG-Maleimide)	Polyethylene glycol spacers to conjugate dyes to biomolecules; improve solubility and pharmacokinetics.
Targeting Ligands (e.g., cRGD, Cetuximab, Affibodies)	Antibodies, peptides, or proteins that confer specific binding to tumor-associated biomarkers (e.g., EGFR, Integrins).
Desalting Columns (Zeba, PD-10)	For rapid purification of conjugated probes from unreacted small-molecule dyes.
NIR-II Imaging System	Comprises a 808 nm or 980 nm laser for excitation, InGaAs camera for detection (>1000 nm), and appropriate long-pass filters.
Matrigel	Basement membrane matrix for establishing orthotopic or primary patient-derived xenograft (PDX) tumor models with relevant microenvironment.
Tissue Phantoms (e.g., Intralipid)	Light-scattering standards to calibrate imaging systems and quantify penetration depth and resolution in vitro.

Designing and Deploying NIR-II Probes: From Molecular Engineering to Intraoperative Workflows

Application Notes

This document outlines the current architectures for NIR-II (1000-1700 nm) fluorescent probes, contextualized within image-guided tumor surgery research. The enhanced tissue penetration and reduced autofluorescence in the NIR-II window offer superior intraoperative visualization of tumor margins and micro-metastases.

Small Molecule Probes

Core Application: Rapid, high-resolution imaging of vasculature and real-time tumor perfusion. Their small size (<5 nm) enables fast pharmacokinetics and renal clearance, reducing long-term toxicity. Key Characteristics: Defined chemical structures, tunable emission via donor-acceptor strength modulation, and relatively straight-forward regulatory pathways. Current research focuses on improving quantum yield and photostability while maintaining biocompatibility. Surgical Utility: Ideal for dynamic contrast-enhanced imaging during surgery, allowing surgeons to distinguish tumor-associated angiogenic vessels from normal vasculature in real time.

Organic Nanomaterial Probes

Core Application: Sentinel lymph node mapping and targeted tumor accumulation for margin delineation. Includes polymer-based nanoparticles, liposomes, and semiconducting polymer nanoparticles (SPNs). Key Characteristics: Larger size (10-150 nm) facilitates passive targeting via the Enhanced Permeability and Retention (EPR) effect. High biocompatibility and potential for high payloads of fluorophores or drugs. SPNs, in particular, exhibit exceptional brightness and photostability. Surgical Utility: Provides prolonged, stable signal for pre-operative planning and intraoperative guidance over extended procedures. Can be functionalized for active targeting of specific tumor biomarkers.

Inorganic Nanoparticle Probes

Core Application: Multiplexed imaging and high-sensitivity detection of deep-seated or residual micro-tumors. Includes rare-earth-doped nanoparticles (RENPs), quantum dots (QDs), and carbon nanotubes. Key Characteristics: Superior optical properties: sharp emission bands (RENPs), size-tunable emission (QDs), and intrinsic NIR-II fluorescence (single-wall carbon nanotubes). Often exhibit high quantum yields and resistance to photobleaching. Surgical Utility: Enables multi-spectral imaging to distinguish different tissue types or tumor subtypes simultaneously. Their high brightness allows detection of sub-millimeter residual disease.

Comparative Quantitative Data

Table 1: Comparative Properties of NIR-II Probe Platforms

Property	Small Molecules	Organic Nanomaterials	Inorganic Nanoparticles
Typical Size Range	0.5 - 2 nm	10 - 150 nm	3 - 50 nm (core)
Quantum Yield (NIR-II)	0.1% - 5%	1% - 20% (SPNs up to ~10%)	5% - 30% (RENPs: up to ~10%)
Ex/Emm Max (nm)	650-850 / 900-1300	680-800 / 1000-1350	Varies (e.g., RENPs: 980 / 1525; QDs: Tunable)
Circulation Half-life	Minutes to ~1 hour	Hours to days (~2-24h)	Days to weeks
Primary Clearance Route	Renal	Reticuloendothelial System (RES) / Hepatic	RES / Hepatic (long-term retention)
Typical Molar Extinction (M⁻¹cm⁻¹)	10⁵ - 10⁶	10⁸ - 10⁹ (per particle)	10⁸ - 10¹¹ (per particle)
Ease of Functionalization	Moderate (covalent chemistry)	High (surface groups, encapsulation)	Moderate/High (ligand exchange, coating)
Key Surgical Advantage	Real-time dynamic imaging	Stable, bright signal for margins	Deep-tissue, multiplexed detection

Experimental Protocols

Protocol 1: Synthesis and Purification of a Heptamethine Cyanine-Based Small Molecule Probe (e.g., CH-4T)

This protocol details the synthesis of a representative donor-acceptor-donor (D-A-D) small molecule with NIR-II emission.

Materials:

• 2,3,3-Trimethylindolenine, 1,4-dihydroxybenzene, 2-thiophenecarboxaldehyde.
• Acetic anhydride, sodium acetate, toluene.
• Dichloromethane (DCM), methanol, hexanes, ethyl acetate.
• Silica gel for column chromatography (200-300 mesh).
• Nitrogen gas line, round-bottom flasks, reflux condenser, rotary evaporator.

Procedure:

• Synthesis of Intermediate (Hemicyanine Salt): In a 100 mL round-bottom flask, dissolve 2,3,3-trimethylindolenine (5 mmol) and 2-thiophenecarboxaldehyde (5 mmol) in 30 mL acetic anhydride. Add a catalytic amount of sodium acetate. Reflux the mixture at 120°C under nitrogen for 6 hours. Cool to room temperature and precipitate the product by adding diethyl ether. Filter and wash with cold ether to obtain the raw hemicyanine salt.
• Synthesis of CH-4T Core: Dissolve the purified hemicyanine salt (2 mmol) and 1,4-dihydroxybenzene (1 mmol) in a mixture of toluene (20 mL) and methanol (5 mL). Add piperidine (0.5 mL) as a catalyst. Reflux under nitrogen for 12 hours.
• Purification: Cool the reaction mixture and remove solvents via rotary evaporation. Redissolve the crude product in minimal DCM. Purify via silica gel column chromatography using a gradient of hexanes to ethyl acetate (from 4:1 to 1:1 v/v) as eluent. Collect the main green band.
• Characterization: Confirm structure and purity via NMR (¹H, ¹³C) and high-resolution mass spectrometry (HRMS). Determine absorption/emission spectra in dichloromethane.

Protocol 2: Preparation and Characterization of PEGylated Semiconducting Polymer Nanoparticles (SPNs)

This protocol describes nanoprecipitation for producing stable, biocompatible organic NIR-II nanoparticles.

Materials:

• NIR-II absorbing semiconducting polymer (e.g., PDPP-DBT or derivatives).
• Amphiphilic polymer (e.g., Polystyrene-b-polyethylene glycol, PS-PEG-COOH).
• Tetrahydrofuran (THF), anhydrous, HPLC grade.
• Deionized water (Milli-Q grade, 18.2 MΩ·cm).
• Probe sonicator, dialysis tubing (MWCO 10-14 kDa), 0.22 μm syringe filters.

Procedure:

• Polymer Solution Preparation: Separately dissolve the semiconducting polymer and the PS-PEG-COOH in THF at a concentration of 1 mg/mL. Mix the two solutions at a desired mass ratio (typically 1:1 to 1:3 polymer:PS-PEG).
• Nanoprecipitation: Rapidly inject 1 mL of the mixed THF solution into 10 mL of vigorously stirred deionized water using a pipette. Continue stirring for 1 hour at room temperature to allow for THF evaporation and nanoparticle self-assembly.
• Purification: Transfer the nanoparticle suspension to dialysis tubing and dialyze against 2 L of deionized water for 24 hours, changing water at least 3 times, to remove THF and free polymer.
• Sterilization and Storage: Filter the dialyzed suspension through a 0.22 μm sterile syringe filter. Concentrate using centrifugal filter units (if needed). Characterize size and zeta potential via dynamic light scattering (DLS). Store at 4°C protected from light.

Protocol 3: Conjugation of a Targeting Ligand (cRGD) to Nanoparticle Surface

Active targeting protocol applicable to both organic and inorganic nanoparticles with surface carboxyl groups.

Materials:

• PEGylated nanoparticles with surface -COOH groups (from Protocol 2 or commercial).
• Cyclo(Arg-Gly-Asp-D-Phe-Cys) peptide (cRGDfC).
• 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS).
• Phosphate Buffered Saline (PBS, 0.01 M, pH 7.4).
• Amicon Ultra centrifugal filters (MWCO appropriate for nanoparticles).
• Shaker or rotator.

Procedure:

• Activation of Carboxyl Groups: In 1 mL of PBS, mix the nanoparticle suspension (containing ~5 nmol of surface -COOH) with a fresh solution of EDC (100x molar excess to -COOH) and NHS (200x molar excess). React for 15 minutes at room temperature with gentle shaking.
• Ligand Conjugation: Add the cRGDfC peptide (a 50x molar excess to original -COOH groups) directly to the activation mixture. Adjust pH to 7.4 if necessary. Allow the coupling reaction to proceed for 2 hours at room temperature with shaking.
• Purification: Purify the conjugated nanoparticles from excess reagents and free peptide by centrifuging through Amicon Ultra filters (3x, PBS wash). Resuspend in sterile PBS.
• Validation: Confirm conjugation success via a change in zeta potential (less negative due to peptide) or using a fluorescently labeled peptide variant in a control reaction. Perform in vitro cell binding assay using αvβ3 integrin-positive (e.g., U87MG) and negative cells.

Visualizations

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II Probe Development & Evaluation

Item	Function & Rationale
NIR-II Fluorophores (e.g., CH-4T, IR-1061)	Core imaging agents. Provide the NIR-II emission signal. Choice defines fundamental optical and pharmacokinetic properties.
Amphiphilic Polymers (e.g., PS-PEG-COOH, DSPE-PEG)	For nanoparticle stabilization and stealth. PEG confers biocompatibility, prolonged circulation, and provides functional groups (-COOH, -NH₂) for ligand conjugation.
Semiconducting Polymers (e.g., PDPP-based polymers)	High-brightness core for organic nanoparticles. Offer high molar absorptivity and tunable emission in the NIR-II region.
Rare-Earth Salts (e.g., YbCl₃, ErCl₃)	Precursors for inorganic RENPs. Ytterbium (Yb³⁺) is the primary NIR-II emitter (≈1525 nm) when sensitized with neodymium (Nd³⁺) or erbium (Er³⁺).
Bioconjugation Kits (EDC/Sulfo-NHS)	Standard chemistry for coupling carboxylic acids to primary amines. Essential for attaching targeting ligands (peptides, antibodies) to nanoparticle surfaces.
Targeting Ligands (e.g., cRGD peptide, Anti-EGFR)	Enable active targeting of tumor-specific biomarkers (integrins, EGFR, etc.), improving probe specificity and accumulation.
Size-Exclusion Chromatography Columns (e.g., Sephadex G-25, PD-10)	For rapid purification of probes from unreacted small molecules, salts, or free ligands. Critical for reproducible in vivo studies.
Dialysis Tubing (MWCO 3.5-14 kDa)	For slow, gentle purification and buffer exchange of nanoparticle suspensions, removing organic solvents and small impurities.
NIR-II Calibration Standards (e.g., IR-26 dye in DCE)	Quantum yield reference standard. Essential for accurate quantification of probe brightness, a key performance metric.
Matrigel or Other ECM Hydrogels	For creating in vitro 3D tumor spheroid models that better mimic tumor microenvironment for probe penetration and binding studies.

This Application Note provides detailed experimental protocols and quantitative comparisons of targeting strategies for Near-Infrared Window II (NIR-II, 1000-1700 nm) fluorescent probes. The content is framed within a broader thesis on developing advanced probes for real-time, high-resolution image-guided tumor surgery. The enhanced tissue penetration and reduced autofluorescence of NIR-II light make these probes ideal for intraoperative visualization of malignant margins. This document focuses on the two primary strategies for achieving tumor accumulation: the passive Enhanced Permeability and Retention (EPR) effect and active targeting using ligands such as antibodies and peptides.

Quantitative Comparison of Targeting Strategies

Table 1: Key Performance Metrics of Targeting Strategies for NIR-II Probes

Parameter	Passive (EPR)	Active (Antibody)	Active (Peptide)
Typical Tumor Accumulation (%ID/g)*	2-8 %ID/g	5-15 %ID/g	4-12 %ID/g
Optimal Time Post-Injection (TPI)	24-48 hours	24-72 hours	4-24 hours
Tumor-to-Background Ratio (TBR)	2-5	5-20	3-10
Primary Driver	Leaky vasculature, poor drainage	High-affinity antigen binding	High-affinity receptor binding
Key Limitation	Heterogeneous across tumors	Slow clearance, high liver uptake	Potential rapid renal clearance
Probe Size (Typical)	>10 nm (e.g., polymers, NPs)	~10-15 nm (IgG conjugates)	<5 nm (small molecule conjugates)
Clinical Translation Stage	Several approved (e.g., Onivyde)	Multiple in trials (e.g., Trastuzumab-IRDye800CW)	Several in preclinical/early trials
Impact on Surgery	Defines tumor bulk	Can detect sub-millimeter micrometastases	Rapid visualization, potentially same-day surgery

*%ID/g: Percentage of Injected Dose per gram of tissue.

Table 2: Characteristics of Common Active Targeting Ligands for NIR-II Probes

Ligand Type	Example Target	Example Ligand	Conjugation Chemistry	Key Advantage for NIR-II
Antibody	HER2	Trastuzumab	NHS ester to lysine, Click chemistry	High specificity, long tumor residence
Humanized mAb	EGFR	Cetuximab	Maleimide to reduced interchain disulfides	Reduced immunogenicity
Peptide	αvβ3 Integrin	RGD (cyclic)	SPDP, Maleimide to cysteine, Click chemistry	Fast penetration, rapid clearance from blood
Peptide	Somatostatin Receptor	Octreotate	Amide coupling to N-terminus	High affinity for neuroendocrine tumors
Affibody	HER2	ZHER2:2891	Site-specific via introduced cysteine	Small size (~7 kDa), rapid targeting

Detailed Experimental Protocols

Protocol 3.1: Evaluating Passive EPR of a NIR-II Polymer Nanoprobe

Objective: To quantify the passive tumor accumulation of a 20 nm polymeric NIR-II fluorophore (e.g., CH1055-PEG) via the EPR effect in a subcutaneous murine model. Materials:

• NIR-II polymer nanoprobe (1 mg/mL in PBS).
• Mouse model with subcutaneous xenograft (e.g., 4T1, U87MG).
• IVIS Spectrum CT or equivalent NIR-II imager.
• Analytical balance, dissection tools. Procedure:

• Probe Administration: Inject 100 µL of probe solution (100 µg, ~5 mg/kg) via the tail vein in tumor-bearing mice (n=5). Use a control mouse injected with PBS.
• In Vivo Imaging: Anesthetize mice with 2% isoflurane. Acquire NIR-II fluorescence images (Ex: 808 nm, Em: 1100-1700 nm) at time points: 0, 1, 4, 8, 24, 48, and 72 hours post-injection (p.i.).
• Ex Vivo Biodistribution: At 24 and 48 hours p.i., euthanize mice. Excise tumor and major organs (heart, liver, spleen, lungs, kidneys, muscle). Weigh each tissue.
• Fluorescence Quantification: Image all tissues ex vivo using the same NIR-II settings. Use region-of-interest (ROI) analysis to determine average fluorescence intensity in each tissue.
• Data Analysis: Create a standard curve using serial dilutions of the injected probe. Convert tissue fluorescence intensity to percentage of injected dose per gram (%ID/g) of tissue. Calculate Tumor-to-Muscle and Tumor-to-Liver Ratios.

Protocol 3.2: Conjugation of a NIR-II Dye to a Targeting Antibody

Objective: Site-specific conjugation of a maleimide-functionalized NIR-II dye (e.g., IRDye 800CW Maleimide) to a reduced monoclonal antibody (e.g., anti-EGFR Cetuximab). Materials:

• Monoclonal Antibody (2 mg/mL in PBS, pH 7.4).
• IRDye 800CW Maleimide (or equivalent NIR-II dye-maleimide).
• Tris(2-carboxyethyl)phosphine (TCEP) reducing agent.
• Zeba Spin Desalting Columns, 7K MWCO.
• PD-10 Desalting column. Procedure:

• Antibody Reduction: Add 100-fold molar excess of TCEP (from 10 mM stock) to the antibody solution. Incubate at 37°C for 30-60 minutes to reduce interchain disulfides, generating free thiols.
• Purification: Pass the reduced antibody through a Zeba column pre-equilibrated with PBS (pH 7.0, EDTA-free) to remove TCEP. Collect the protein fraction.
• Conjugation: Immediately add a 3-5 fold molar excess of NIR-II dye-maleimide (from DMSO stock) to the reduced antibody. Incubate in the dark at room temperature for 2 hours.
• Purification of Conjugate: Load the reaction mixture onto a PD-10 column equilibrated with PBS. Elute with PBS, collecting 0.5 mL fractions. Identify the protein-containing (colored) fractions.
• Characterization: Measure absorbance at 280 nm (protein) and 780 nm (dye). Calculate the degree of labeling (DOL, dyes per antibody) using the dye's and antibody's extinction coefficients. Validate with SDS-PAGE followed by fluorescence scanning.

Protocol 3.3: In Vivo Validation of an Active Targeting NIR-II Probe

Objective: Compare the tumor targeting efficacy of an active probe (e.g., cRGD-CH1055) versus its non-targeted control (e.g., PEG-CH1055) in an integrin αvβ3-positive tumor model. Materials:

• Active targeting probe (cRGD-CH1055).
• Passive control probe (PEG-CH1055).
• U87MG tumor-bearing nude mice (n=6 per group).
• Blocking agent: c(RGDyK) peptide (1 mg/mL). Procedure:

• Blocking Study Cohort: Pre-inject one group of mice (n=3) with 100 µL of c(RGDyK) peptide (100 µg) 30 minutes before probe injection to saturate the receptors.
• Probe Administration: Inject all mice (blocked and unblocked) with 100 µL of cRGD-CH1055 (~2 nmol) via tail vein. In a separate control group, inject the PEG-CH1055 probe.
• Longitudinal Imaging: Perform NIR-II imaging at 1, 4, 8, and 24 hours p.i. as in Protocol 3.1.
• Quantitative Analysis: At 8 hours p.i., euthanize mice and perform ex vivo biodistribution. Calculate %ID/g and TBR for all groups.
• Statistical Validation: Use one-way ANOVA with post-hoc tests to compare tumor accumulation (%ID/g) between the active probe, blocked group, and passive control. Significance (p < 0.05) confirms active targeting.

Signaling Pathways and Workflow Diagrams

Diagram Title: Passive vs. Active Tumor Targeting Workflow for NIR-II Probes

Diagram Title: Active Probe Internalization and Intracellular Trafficking

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for NIR-II Probe Targeting Studies

Item Name	Supplier Examples	Function in Research
NIR-II Fluorophores	CH1055, IR-1061, FD-1080, IRDye 800CW (NIR-I/II bridge)	The core imaging agent; emits in the 1000-1700 nm range for deep tissue penetration.
Heterobifunctional Linkers	SM(PEG)n (Thermo), Maleimide-PEG-NHS	Enable controlled, site-specific conjugation of dyes to targeting ligands (e.g., antibodies, peptides).
Desalting/Purification Columns	Zeba Spin Columns, PD-10 Columns (Cytiva)	Rapidly remove excess dye, reducing agents, or salts from conjugation reactions.
Tumor Cell Lines	U87MG (high αvβ3), 4T1 (murine breast), SKOV-3 (high HER2)	Provide in vitro and in vivo models with defined target receptor expression for validation.
Animal Models	Nude Mice, SCID Mice	Host for subcutaneous or orthotopic xenografts; allow longitudinal imaging studies.
NIR-II In Vivo Imagers	Princeton NIRVana, Suzhou NIR-Optics MARS, Modified IVIS	Systems capable of excitation (~808 nm) and detection in the NIR-II window for in vivo imaging.
Targeting Ligands	cRGDfK Peptide, Trastuzumab (Anti-HER2), Cetuximab (Anti-EGFR)	Provide the active targeting moiety; determine specificity and accumulation efficiency.
Quantum Yield Standards	IR-26 (QY=0.05%), ICG in DMSO	Used to benchmark and calculate the quantum yield of new NIR-II probes in solution.

Within the broader research thesis on NIR-II (1000-1700 nm) fluorescent probes for image-guided surgery, two paramount intraoperative applications are the real-time delineation of tumor margins and the subsequent assessment for residual disease to confirm a negative margin status. This document provides detailed application notes and protocols for implementing these techniques in preclinical and translational research settings.

Application Notes: Principles and Quantitative Benchmarks

The efficacy of NIR-II probes for margin analysis hinges on key optical and biological parameters. The following table summarizes quantitative performance benchmarks for current-state probes as established in recent literature.

Table 1: Quantitative Performance Benchmarks for NIR-II Probes in Margin Delineation

Parameter	Target Range/Value	Significance for Margin Assessment
Peak Emission Wavelength	1000 - 1350 nm	Minimizes tissue scattering & autofluorescence for deeper, clearer margin visualization.
Quantum Yield (in serum/plasma)	> 5%	Ensures sufficient signal brightness for real-time imaging.
Brightness (ϵ × Φ)	> 1 x 10⁴ M⁻¹cm⁻¹	Critical for detecting sparse residual tumor foci at margins.
Tumor-to-Background Ratio (TBR)	> 3.5 (in vivo)	Enables unambiguous discrimination between tumor and healthy tissue.
Pharmacokinetic Clearance (Blood Half-life)	1 - 6 hours (probe-dependent)	Balances sufficient tumor accumulation with rapid background clearance.
Optimal Imaging Time Window	6 - 48 h post-injection	Probe-specific period for peak TBR.
Spatial Resolution (NIR-II vs NIR-I)	2-3x improvement	Enables detection of sub-millimeter residual tumor clusters (< 1 mm).
Penetration Depth	5 - 10 mm	Allows assessment of deep surgical beds and underlying tissue layers.

Table 2: Comparison of Probe Targeting Strategies for Margin Detection

Targeting Strategy	Example Probe/Target	Advantages	Limitations	Best Suited For
Passive (EPR effect)	PEGylated CNTs, Ag₂S QDs	Simple design, broad applicability.	Lower specificity, variable EPR across tumors.	Fast screening, vascularized tumors.
Active (Targeted)	cRGD-ICG derivatives (integrin αvβ3), Anti-EGFR antibodies	High specificity, potentially lower dosage.	Requires validated target expression, more complex chemistry.	Cancers with homogeneous target expression (e.g., GBM, HNSCC).
Activity-Based (Activatable)	Protease-cleavable probes (MMP-2/9, Cathepsin)	Signal-on only in tumor microenvironment, ultra-high TBR.	Complex molecular design, potential for false negatives.	Infiltrative tumors with high protease activity (e.g., breast, pancreas).
Metabolic/Physiological	IRDye 800CW 2-DG (Glucose metabolism)	Reflects tumor pathophysiology, rapid uptake.	Can highlight inflammatory tissue, moderate specificity.	High-metabolism tumors (e.g., sarcoma, NSCLC).

Title: Intraoperative NIR-II Margin Assessment Workflow

Detailed Experimental Protocols

Protocol 1:In VivoPreclinical Validation of Margin Delineation

Objective: To quantify the accuracy of a NIR-II probe in defining true tumor margins in an orthotopic or subcutaneous mouse model, compared to post-mortem histology.

Materials: See "The Scientist's Toolkit" below.

Procedure:

• Animal Model & Tumor Implantation: Establish a relevant tumor model (e.g., 4T1-Luc mammary carcinoma in BALB/c mice, U87MG glioblastoma in nude mice). Allow tumors to grow to ~5-8 mm in diameter.
• Probe Administration: Inject the NIR-II probe via tail vein at the optimized dose (e.g., 100 µL of 100 µM solution). Anesthetize the animal.
• In Vivo Imaging (Pre-Resection): At the predetermined peak TBR time point: a. Place the animal in the NIR-II imaging system. b. Acquire a brightfield image. Acquire a NIR-II fluorescence image using appropriate laser excitation and emission filters (e.g., 808 nm ex, 1000 nm long-pass em). c. Use software to generate an overlay image. Manually or semi-automatically draw a region of interest (ROI) around the fluorescent signal boundary. This defines the imaging-predicted margin.
• Simulated Surgery & Ex Vivo Imaging: a. Euthanize the animal. Excise the entire tumor with a ~2-3 mm cuff of surrounding normal tissue. b. Image the freshly resected specimen immediately under the NIR-II system from multiple angles. Precisely mark any fluorescent areas extending to the specimen's edge on the tissue with sterile ink. c. Section the specimen along the plane corresponding to the primary in vivo image. Image the cut face (ex vivo surface).
• Histopathological Correlation (Gold Standard): a. Fix the sectioned tissue in 10% neutral buffered formalin for 24h. b. Process, embed in paraffin, and section at 5 µm thickness. c. Perform H&E staining. A pathologist, blinded to the fluorescence images, will outline the true histopathological margin (interface between last cancer cell and normal tissue).
• Data Analysis: a. Co-register the in vivo fluorescence overlay image and the photograph of the H&E slide using fiducial markers or tissue landmarks. b. Calculate metrics: * Sensitivity: (True Positive Area / Histologically Positive Area) x 100. * Specificity: (True Negative Area / Histologically Negative Area) x 100. * Accuracy of Margin Width: Measure the distance from the fluorescence boundary to the histological boundary at multiple (e.g., 12) radial points. Report mean ± SD. * Positive Predictive Value (PPV) for Residual Tumor: For ex vivo specimen imaging, calculate PPV of fluorescent spots at the cut edge for harboring tumor cells on histology.

Protocol 2: Intraoperative Negative Margin Assessment Protocol for Resected Specimens

Objective: To establish a standardized method for intraoperative, ex vivo assessment of surgical specimen margins using a NIR-II imaging box system.

Materials: NIR-II imaging box, specimen mounting stage, calibration phantom, forceps.

Procedure:

• System Calibration: Prior to surgery, power on the NIR-II imaging box and allow the camera to cool. Image a calibration phantom containing serial dilutions of the probe to ensure linear response.
• Specimen Handling: Immediately after resection, orient the specimen on a sterile field. Do not place in formalin. Use ink or sutures to mark anatomical orientation (e.g., superior, medial).
• Initial Survey Scan: Place the intact specimen on the imaging stage inside the box. Acquire a rapid NIR-II fluorescence scan (~10-30 seconds) to identify "hot spots."
• Margin-Specific Imaging: a. If the specimen is large, serially section it at 3-5 mm intervals perpendicular to the presumed plane of resection. b. Lay each section flat, cut-face-down, on the stage. c. Acquire high-resolution fluorescence and brightfield images.
• Image Analysis & Thresholding: a. Use integrated software to apply a standardized signal-to-background ratio (SBR) threshold. This threshold should be pre-validated against histology in preclinical models (e.g., SBR > 2.5 indicates high risk of positive margin). b. The software highlights areas where fluorescence extends to within 1 mm of the specimen edge (the "margin").
• Intraoperative Reporting: Generate a diagrammatic report overlay showing the specimen outline and locations of concerning fluorescent foci. Relay this to the surgeon within 15 minutes. The surgeon can then target re-excision from the corresponding region of the wound bed.
• Histology Correlation: The fluorescent foci and adjacent control non-fluorescent margins are marked with different colored inks, submitted separately for standard pathological processing, and analyzed for tumor presence to validate the imaging readout.

Title: NIR-II Probe Tumor Targeting Mechanisms

The Scientist's Toolkit

Table 3: Essential Research Reagent Solutions & Materials

Category	Item/Reagent	Function & Brief Explanation
NIR-II Probes	Organic Dyes (e.g., CH1055 derivatives)	Small molecule dyes; tunable chemistry, moderate brightness, renal clearable.
	Quantum Dots (e.g., Ag₂S, Ag₂Se, PbS)	Inorganic nanoparticles; high brightness and photostability, but potential long-term toxicity concerns.
	Single-Walled Carbon Nanotubes (SWCNTs)	Nanomaterials; intrinsically emit in NIR-II, used for angiogenesis imaging.
	Lanthanide Nanoparticles (e.g., NaYF₄:Yb,Er)	Upconversion or downshifting particles; sharp emission peaks, high stability.
Imaging Systems	InGaAs Camera	The essential detector for NIR-II light, requires cooling (often to -80°C) to reduce dark noise.
	808 nm or 980 nm Laser	Common excitation sources for NIR-II probes, with appropriate power density for safe in vivo use.
	Long-pass Emission Filters (1000 nm, 1200 nm, 1500 nm)	Filters that block excitation light and NIR-I autofluorescence, collecting only NIR-II signal.
	Imaging Box/Clinical System Prototype	A light-tight enclosure with integrated laser, filter wheels, and camera for standardized specimen imaging.
Biological Reagents	Matrigel	Basement membrane matrix for orthotopic tumor cell implantation.
	D-Luciferin (for bioluminescent models)	Substrate for firefly luciferase-expressing tumor cells; enables cross-validation of tumor location.
	Isoflurane/Oxygen Mix	Standard inhalation anesthetic for maintaining animal anesthesia during imaging and surgery.
	Phosphate Buffered Saline (PBS)	Vehicle for probe dilution and injection, and for tissue rinsing during ex vivo imaging.
Analysis Software	Image Co-registration Software (e.g., 3D Slicer, FIJI/Plugins)	Aligns fluorescence images with histology slides for pixel-level accuracy analysis.
	ROI & Quantification Tools (e.g., LI-COR Image Studio, Living Image)	Measures fluorescence intensity, calculates TBR, and performs thresholding analysis.
Histology Supplies	Optimal Cutting Temperature (O.C.T.) Compound	For freezing fresh tissue specimens for cryosectioning when immediate fluorescence preservation is needed.
	Eosin Y Solution	Counterstain in H&E staining, colors cytoplasm and extracellular matrix pink.
	Hematoxylin Solution	Nuclear stain in H&E, colors cell nuclei blue-purple, critical for identifying tumor cells.
	Antigen Retrieval Buffers (e.g., citrate, EDTA)	For recovering antigenicity in formalin-fixed tissue for immunohistochemistry validation of targets.

This application note details protocols for utilizing near-infrared window II (NIR-II, 1000-1700 nm) fluorescent probes in oncological surgery. The primary objectives are precise intraoperative sentinel lymph node (SLN) mapping and the sensitive detection of micro-metastases. This work is situated within a broader thesis advancing NIR-II fluorophores for improved tumor-to-background ratio (TBR), deeper tissue penetration, and superior spatial resolution over traditional NIR-I imaging, ultimately aiming to enhance surgical precision and patient prognosis.

Key Research Reagent Solutions

Table 1: Essential Research Reagents for NIR-II Guided SLN Mapping

Reagent/Material	Function/Brief Explanation
NIR-II Fluorophores (e.g., CH1055-derivatives, IRDye 800CW, Quantum Dots)	Core imaging agent. Emit light in the 1000-1700 nm range for deep-tissue, high-resolution imaging with minimal autofluorescence.
Targeting Ligands (e.g., cRGD, EGFR mAb, HER2 mAb)	Conjugated to fluorophore for specific binding to tumor cell surface receptors (αvβ3 integrin, EGFR, HER2) to highlight micro-metastases.
PBS (Phosphate Buffered Saline)	Standard buffer for probe dissolution, dilution, and in vivo administration.
Matrigel	Used for orthotopic or subcutaneous tumor implantation in murine models to simulate tumor microenvironment.
Isoflurane/Oxygen Mixture	Standard inhalation anesthetic for maintaining animal sedation during imaging and surgical procedures.
Sterile Surgical Tools (Fine Scissors, Forceps)	For precise dissection and exposure of lymphatics and nodes during image-guided procedures.
NIR-II Fluorescence Imaging System	Contains a 808 nm or 980 nm laser for excitation, InGaAs cameras for NIR-II detection, and software for real-time image overlay and quantification.

Experimental Protocols

Protocol 3.1: Synthesis and Characterization of a Targeted NIR-II Probe (e.g., cRGD-CH1055-PEG)

• Conjugation: React the NHS ester of CH1055-PEG with the primary amine of cyclic RGD (cRGD) peptide in anhydrous DMSO (molar ratio 1:1.2) under argon atmosphere for 4 hours at room temperature.
• Purification: Purify the conjugate via size-exclusion chromatography (PD-10 column) using PBS as the eluent. Collect the colored fraction.
• Characterization:
  • UV-Vis-NIR Spectroscopy: Confirm absorption peak ~750 nm for CH1055.
  • Fluorescence Spectroscopy: Measure emission spectrum (900-1400 nm) upon 808 nm excitation.
  • HPLC: Analyze purity (>95%) using a C18 column with a water/acetonitrile gradient.
  • Dynamic Light Scattering (DLS): Measure hydrodynamic diameter (expected ~10-15 nm).

Protocol 3.2: In Vivo SLN Mapping in a Murine Model

• Animal Preparation: Anesthetize a nude mouse (bearing a relevant tumor xenograft if applicable) using 2% isoflurane in oxygen.
• Probe Injection: Subcutaneously inject 50 µL of the NIR-II probe (e.g., non-targeted CH1055-PEG, 100 µM in PBS) into the hind paw pad.
• Real-Time Imaging: Place the animal in the NIR-II imaging system. Acquire dynamic images (excitation: 808 nm, emission: 1100-1300 nm filter) every 30 seconds for 20 minutes.
• Data Collection: Track the lymphatic flow and identify the primary (popliteal) and secondary (iliac) SLNs as discrete, high-signal foci.
• Ex Vivo Validation: Surgically excise the identified SLNs and adjacent non-SLNs based on fluorescence guidance. Image ex vivo to confirm signal localization.

Protocol 3.3: Intraoperative Detection of Micro-Metastases

• Tumor Model Establishment: Implant tumor cells (e.g., 4T1-Luc2 for breast cancer) orthotopically into the mammary fat pad of a BALB/c mouse.
• Systemic Probe Administration: Allow tumor to grow to ~5-8 mm diameter. Inject 200 µL of the targeted NIR-II probe (e.g., cRGD-CH1055-PEG, 200 µM) via tail vein.
• Optimal Imaging Window: Perform imaging at 24 hours post-injection (time point determined from pharmacokinetic studies for optimal TBR).
• Image-Guided Surgery: Under real-time NIR-II visualization, perform primary tumor resection, preserving the fluorescence overlay.
• Margin & Lymph Node Inspection: Systemically scan the tumor bed for residual fluorescent foci (positive margins). Identify and excise fluorescent SLNs.
• Histological Correlation: Fix all excised tissue in 4% PFA. Process for H&E and immunohistochemistry (IHC) staining. Correlate fluorescent foci with clusters of tumor cells (<2 mm, micro-metastases) under bright-field microscopy.

Table 2: Performance Metrics of Representative NIR-II Probes in SLN Mapping

Probe Type	Emission Max (nm)	SLN Detection Time (s)	Signal-to-Background Ratio (SBR)	Spatial Resolution (mm)	Reference (Example)
CH1055-PEG	1055	~180	12.5 ± 1.8	~0.5	Antaris et al., Nature Materials 2016
IR-1061	1061	~150	15.2 ± 2.1	~0.4	Zhu et al., Nat. Commun. 2018
Ag2S Quantum Dots	1200	~90	32.4 ± 3.5	~0.2	Hong et al., Nat. Biotechnol. 2012
Non-Targeted Polymer Dots	1300	~120	25.7 ± 2.8	~0.3	Li et al., Nat. Commun. 2018

Table 3: Efficacy of Targeted vs. Non-Targeted Probes in Micro-Metastasis Detection

Probe (Tumor Model)	Primary Tumor TBR	Micro-Metastasis Detection Sensitivity	Detection Limit (Cluster Size)	False Positive Rate (in Reactive LN)
cRGD-CH1055-PEG (U87MG)	8.3 ± 0.9	95%	~0.3 mm	<5%
Non-Targeted CH1055-PEG (U87MG)	3.1 ± 0.5	40%	~1.0 mm	~0%
Anti-EGFR-mAb-IRDye800CW (A431)	6.5 ± 1.2 (NIR-I)	85%*	~0.5 mm*	10%
Targeted Polymer Dots (4T1)	12.8 ± 1.7	98%	~0.2 mm	<3%

*Data from NIR-I system shown for comparison.

Signaling Pathways & Experimental Workflows

1. Introduction Within the broader thesis on NIR-II (1000-1700 nm) fluorescent probes for image-guided tumor surgery, translating promising research into clinical utility hinges on seamless integration with existing surgical ecosystems. This necessitates compatibility with both the physical imaging hardware and standardized clinical workflows. This document provides detailed application notes and protocols for integrating NIR-II imaging systems with surgical infrastructure, focusing on intraoperative tumor margin delineation and sentinel lymph node mapping.

2. Compatible Imaging Hardware: Specifications and Integration Current surgical NIR-II imaging systems are designed as modular adjuncts to existing operating room (OR) setups, primarily white-light endoscopy/laparoscopy and robotic surgery systems.

Table 1: Representative NIR-II Compatible Surgical Imaging Systems & Key Specifications

System/Component	Detection Method	NIR-II Excitation (nm)	NIR-II Emission Filter (nm)	Field of View	Integration Method
Open-field Camera	InGaAs or cooled Si-CCD	808 or 980	Long-pass >1000 or 1100-1700 bandpass	15-30 cm	Ceiling-mounted arm or tripod; co-registers with white-light view.
Laparoscopic/Endoscopic	Fiber-coupled InGaAs	808	Long-pass >1000	Determined by scope	Clip-on filter adaptor or custom dual-channel scope.
Da Vinci Robotic System	Optical adapter module	808	1000-1700 bandpass	Aligns with stereo viewer	Interchangeable with standard endoscope; feeds to surgeon's console.
Microscope-integrated	Beam splitter + InGaAs	785 or 808	Short-pass <900 for excitation rejection	Matches ocular FOV	Optical path integrated into surgical microscope body.

3. Detailed Experimental Protocols

Protocol 3.1: Ex Vivo Tumor Margin Assessment Using NIR-II Fluorescent Probes Objective: To quantify and visualize residual tumor on excised tissue specimens using a benchtop NIR-II imaging system, simulating intraoperative margin analysis. Materials:

• NIR-II fluorescent probe (e.g., IRDye 800CW, CH-4T, or a targeting probe like cRGD-X).
• Benchtop NIR-II imaging system (e.g., equipped with 808 nm laser, 1000 nm long-pass filter, InGaAs camera).
• Fresh human or murine tumor resection specimens.
• Phosphate-buffered saline (PBS).
• Black imaging stage.

Procedure:

• Probe Administration Simulation: If using a targeting probe, incubate the fresh tissue specimen in a solution of the probe (e.g., 100 nM in PBS) for 20 minutes at room temperature.
• Washing: Rinse the specimen gently but thoroughly with PBS three times (1 min each) to remove unbound probe.
• Imaging Setup: a. Place the specimen on a black non-reflective stage. b. Position the imaging head approximately 20 cm above the specimen. c. Set excitation laser power to 50 mW/cm² (ensure eye safety protocols). d. Set camera acquisition parameters: integration time = 100-500 ms, gain = medium.
• Image Acquisition: a. Acquire a white-light reference image. b. Acquire the NIR-II fluorescence image under laser excitation. c. Acquire a background image (laser on, specimen out of FOV) for subtraction.
• Analysis: a. Subtract the background image from the fluorescence image. b. Use region-of-interest (ROI) tools to calculate Signal-to-Background Ratio (SBR) of suspected tumor regions vs. adjacent normal tissue. c. Overlay false-color NIR-II image onto the white-light image at 30-50% opacity for visualization.

Protocol 3.2: Intraoperative Sentinel Lymph Node (SLN) Mapping Protocol Objective: To guide the precise intraoperative identification and resection of SLNs using a NIR-II fluorescent probe and compatible imaging hardware. Materials:

• FDA-approved or investigational NIR-II contrast agent (e.g., Indocyanine Green (ICG) for its NIR-II tail emission).
• Compatible NIR-II laparoscopic/robotic system (see Table 1).
• Standard surgical instruments for SLN biopsy.

Procedure:

• Preoperative Planning: Obtain institutional review board (IRB) approval and informed consent.
• Probe Injection: In the operating room, inject 500-1000 µL of ICG solution (typically 0.5-1.0 mg/mL) peritumorally or in the defined anatomical drainage area.
• Dynamic Imaging: a. Position the integrated NIR-I/II imaging scope over the surgical field. b. Initiate real-time fluorescence video acquisition immediately post-injection. c. Observe the lymphatic channel draining the fluorescent signal and track it to the first (sentinel) lymph node(s). This typically occurs within 5-15 minutes.
• Guidance and Resection: a. Switch the display between pure white-light, pure NIR-II, and overlay modes to guide dissection. b. Using the fluorescent signal as a guide, carefully dissect down to the identified SLN(s). c. Confirm complete nodal resection by verifying the absence of residual high-intensity fluorescent signal in the nodal bed.
• Ex Vivo Confirmation: Image the resected node ex vivo using the same system to confirm strong fluorescence signal prior to sending for pathological analysis.

4. Visualization of Workflows and Pathways

Diagram Title: SLN Mapping Clinical Workflow

Diagram Title: Ex Vivo Margin Assessment Protocol

5. The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II Image-Guided Surgery Research

Item	Function/Description	Example Products/Vendors
Targeted NIR-II Probes	Fluorescent conjugates that bind to tumor-specific biomarkers (e.g., EGFR, PSMA) for specific labeling.	cRGD-PEG-CH1055; Anti-EGFR-IRDye 800CW; LICOR, Lumiprobe.
Non-targeted NIR-II Dyes	High quantum yield fluorophores for vascular/lymphatic imaging and perfusion assessment.	CH-4T, IR-12N, IRDye 800CW; Ffranck, LICOR.
ICG (Indocyanine Green)	FDA-approved NIR-I dye with substantial NIR-II emission; the clinical benchmark for translation studies.	Diagnostic Green, Akorn.
NIR-II Phantoms	Tissue-simulating materials with known optical properties for system validation and calibration.	India ink, intralipid-based gels; custom from bio-optics labs.
Murine Tumor Models	Immunocompetent or xenograft models for in vivo efficacy and pharmacokinetic studies.	4T1 (murine mammary), U87MG (human glioma) xenografts.
Surgical Simulators	Phantoms or ex vivo tissue models for practicing and optimizing imaging-guided resection techniques.	Custom 3D-printed phantoms with dye-filled "tumor" inclusions.

Optimizing NIR-II Probes: Solving Brightness, Safety, and Specificity Challenges

Within the broader thesis on developing NIR-II (1000-1700 nm) fluorescent probes for precision image-guided tumor surgery, this document details practical strategies for optimizing probe pharmacokinetics (PK) and biodistribution (BD). The goal is to engineer probes with enhanced tumor-to-background ratio (TBR), rapid systemic clearance from non-target tissues, and sufficient tumor residence time for intraoperative imaging. The three critical, tunable parameters are hydrophilicity, hydrodynamic size, and surface charge.

Core Principles and Quantitative Effects

Modulating physicochemical parameters directly influences the probe's interaction with biological systems, impacting plasma half-life, liver/spleen sequestration, renal clearance, and tumor accumulation via the Enhanced Permeability and Retention (EPR) effect or active targeting.

Table 1: Impact of Physicochemical Modulations on Probe Behavior

Parameter	Increased Effect	Primary PK/BD Consequence	Optimal Range for NIR-II Tumor Probes
Hydrophilicity (e.g., PEGylation, carboxylates)	Reduced non-specific protein adsorption (opsonization)	Increased blood circulation time; Reduced liver uptake	PEG MW: 2-5 kDa; Moderate to high hydrophilicity
Hydrodynamic Size	Slows diffusion; affects renal filtration threshold	Size > 10 nm: Reduced renal clearance, increased EPR; Size < 6 nm: Rapid renal clearance	10-30 nm (for long-circulating, EPR-dependent probes)
Surface Charge	Alters interaction with negatively charged cell membranes & proteins	Positive: Enhanced cellular uptake, but high liver/spleen sequestration; Negative/Slightly Negative: Reduced non-specific uptake, longer circulation	Slightly Negative to Neutral Zeta Potential (-10 to +10 mV)

Application Notes & Protocols

AN-1: Modulating Hydrophilicity via PEGylation

Objective: To increase circulation half-life and reduce mononuclear phagocyte system (MPS) uptake of a hydrophobic NIR-II dye core. Reagent Solutions:

• NIR-II Dye-NHS Ester: (e.g., CH-1055, IR-FEP) Reactive for amine conjugation.
• Amine-PEGₙ₋Carboxylic Acid (n=2-5 kDa): Heterobifunctional linker.
• Sulfo-Cy5.5 Maleimide (Control): For orthogonal labeling validation.
• HPLC Purification System (C18 Column): For critical purification.

Protocol:

• Conjugation: Dissolve 5 mg of amine-PEG₅ₖ-COOH in 1 mL of anhydrous DMSO. Add 2 molar equivalents of NIR-II dye-NHS ester and 3 equivalents of DIEA. React under argon at 25°C for 4h.
• Purification: Dilute reaction mixture 1:10 with Milli-Q water. Purify via semi-preparative HPLC (C18 column, gradient: 20% to 95% acetonitrile in 0.1% TFA over 30 min). Collect the major peak (typically later eluting than unreacted dye).
• Validation: Lyophilize the product. Confirm conjugation via MALDI-TOF (expected mass increase ~5 kDa). Confirm hydrophilicity increase by measuring logP (octanol/water partition coefficient); target logP < -0.5.

AN-2: Controlling Size via Macromolecular Assembly

Objective: To assemble a controlled ~20 nm nanoparticle probe for optimized EPR effect. Reagent Solutions:

• PEGylated NIR-II Dye (from AN-1): Hydrophilic monomer.
• Human Serum Albumin (HSA) or Bovine Serum Albumin (BSA): Biocompatible scaffold.
• Dynamic Light Scattering (DLS) / Zetasizer: For size and Zeta potential measurement.
• NIR-II Imaging System: For in vitro validation.

Protocol:

• Assembly: Dissolve 10 mg of HSA in 1 mL of PBS (pH 7.4). Add 0.2 mg of PEGylated NIR-II dye dropwise while stirring. Incubate at 4°C for 12h.
• Size Isolation: Filter the solution through a 0.22 µm membrane. Fractionate using size-exclusion chromatography (Sephadex G-100, PBS eluent). Collect fractions.
• Characterization: Analyze each fraction by DLS. Pool fractions with a polydispersity index (PDI) < 0.2 and hydrodynamic diameter of 15-25 nm. Measure Zeta potential in 1 mM KCl.

AN-3: Tuning Surface Charge via Functional Groups

Objective: To evaluate the effect of surface charge on biodistribution using variants of a nano-probe. Reagent Solutions:

• HSA-NIR-II Nanoparticle (from AN-2): Base material (slightly negative).
• 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) / N-Hydroxysuccinimide (NHS): Carboxyl activation reagents.
• Cetyltrimethylammonium Bromide (CTAB): For positive charge coating.
• Heparin Sodium: For enhanced negative charge coating.

Protocol:

• Negative Charge Enhancement: Activate carboxyls on HSA nanoparticle with EDC/NHS (5 mM/10 mM, 15 min). React with 10-fold molar excess of ethanolamine (neutral control) or heparin (negative) for 2h. Purify via centrifugal filtration (100 kDa MWCO).
• Positive Charge Coating: Incubate HSA nanoparticle with 0.1% w/v CTAB for 1h at 25°C. Purify via extensive dialysis against PBS.
• Charge Measurement: Determine the Zeta potential for each variant (CTAB+: +15 to +30 mV; Native: -10 to -20 mV; Heparin: -25 to -40 mV).

Validation Protocol:In VivoBiodistribution Study

Objective: To quantitatively compare the performance of optimized probes. Animal Model: BALB/c nude mice with subcutaneous 4T1 tumors (~150 mm³). Groups: (n=4 per group) Inject 100 µL of probe variant (0.5 mg/kg) via tail vein. Imaging: Acquire NIR-II images at 1, 4, 12, 24, and 48h post-injection. Use regions of interest (ROIs) to calculate signal intensity in tumor, liver, and muscle. Analysis: Calculate Tumor-to-Background Ratio (TBR = Tumor SNR / Muscle SNR) and quantify %Injected Dose per Gram (%ID/g) in harvested organs via fluorescence spectrophotometry.

Table 2: Expected In Vivo Outcomes from Probe Variants

Probe Variant	Key Properties	Expected Plasma t₁/₂	Expected Tumor Accumulation (24h)	Expected Liver Uptake
PEGylated, 12 nm, Slight Negative	Optimal Hydrophilicity, Renal Borderline, Optimal Charge	Long (~6-8h)	High (>8 %ID/g)	Low
Non-PEGylated, 8 nm, Neutral	Hydrophobic, Small, Neutral	Short (~0.5h)	Low (<3 %ID/g)	Moderate
PEGylated, 30 nm, Strong Positive	Hydrophilic, Large, Positive Charge	Moderate (~2h)	Moderate	Very High

Diagrams

Title: Probe Design Parameters Influence Biodistribution

Title: NIR-II Probe Synthesis and Optimization Workflow

The Scientist's Toolkit: Key Reagent Solutions

Table 3: Essential Materials for NIR-II Probe Optimization

Item	Function in Context	Example/Note
Heterobifunctional PEG Linkers (e.g., NH₂-PEG-COOH)	Critical for conjugating dyes to biomolecules, imparting hydrophilicity, and providing a functional handle for further modification.	MW: 2k, 5k Da; Use with NHS/EDC chemistry.
NIR-II Dye Reactive Esters (NHS, Maleimide)	Enable controlled, covalent conjugation to amines or thiols on targeting ligands, proteins, or PEG linkers.	CH-1055, IR-FEP, IRDye 800CW derivatives.
Size-Exclusion Chromatography (SEC) Media (e.g., Sephadex G-100)	For separating probe monomers from aggregates and isolating nanoparticles by hydrodynamic size.	Essential for obtaining monodisperse fractions.
Dynamic Light Scattering (DLS) / Zeta Potential Analyzer	The primary instrument for measuring hydrodynamic diameter, polydispersity (PDI), and surface charge (Zeta potential).	Key for characterizing size and charge modulations.
Small Animal NIR-II Fluorescence Imager	Validates probe performance in vivo by quantifying tumor accumulation and pharmacokinetics in real time.	Requires InGaAs camera for 1000-1700 nm detection.
Centrifugal Filter Units (MWCO)	For rapid buffer exchange, concentration, and purification of probe conjugates based on molecular weight cut-off.	Use 10-100 kDa MWCO depending on probe size.

The development of NIR-II (1000-1700 nm) fluorescent probes for image-guided tumor surgery offers unparalleled advantages in spatial resolution and tissue penetration. However, the clinical translation of these agents is critically dependent on their pharmacokinetic profile, specifically their route and rate of systemic clearance. The two primary pathways—renal and hepatic elimination—profoundly influence both the safety and efficacy of these probes.

Renal clearance, typically via glomerular filtration of small, hydrophilic molecules, offers rapid removal from the body, minimizing background signal and potential long-term toxicity. Hepatic clearance, involving metabolism and biliary excretion, is suited for larger, more lipophilic compounds but carries risks of hepatotoxicity, metabolite-related toxicity, and enterolepatic recirculation. For NIR-II probes, engineering the molecular properties to steer clearance through the preferred pathway is a central design strategy to mitigate toxicity and ensure patient safety.

Quantitative Comparison of Elimination Pathways

Table 1: Key Characteristics of Renal vs. Hepatic Elimination Pathways

Parameter	Renal Elimination	Hepatic Elimination
Primary Driver	Glomerular Filtration	Hepatocyte Uptake & Metabolism
Ideal Molecular Weight	< 60 kDa (typically < 10 kDa for small molecules)	Variable, often higher
Ideal Charge/Hydrophilicity	Hydrophilic, charged	Amphiphilic to lipophilic
Clearance Rate	Often rapid (minutes to hours)	Can be slower (hours to days)
Key Toxicity Risks	Nephrotoxicity (if tubular uptake/secretion), prolonged retention in renal impairment	Hepatotoxicity, reactive metabolites, biliary obstruction
Impact on NIR-II Imaging	Low background post-clearance; fast kinetics require rapid imaging.	Potential liver/spleen background signal; slower kinetics allow longer imaging windows.
Modifiability via Probe Design	High (via size, charge, hydrophilicity tuning)	High (via lipophilicity, substrate recognition motifs)

Table 2: Example NIR-II Probes and Their Reported Clearance Pathways

Probe Name / Core Structure	Primary Clearance Pathway	Half-life (in mice, approx.)	Rationale & Notes
IRDye 800CW	Renal	~1-3 hours	Small hydrophilic molecule, fits glomerular pore size.
CH1055 Derivative	Renal/Hepatic (Mixed)	~2-4 hours	Engineered with sulfonate groups to enhance hydrophilicity and renal clearance.
Quantum Dots (CdSe/ZnS)	Hepatic (RES uptake)	Days to weeks	Large size leads to opsonization and sequestration by liver/spleen macrophages (RES).
Single-Walled Carbon Nanotubes	Hepatic (Biliary)	Days	High aspect ratio and surface functionalization influence RES uptake and biliary excretion.
Lipoic Acid-based Dots (LADs)	Predominantly Renal	~4-6 hours	Compact size and surface chemistry designed to evade RES and promote renal filtration.

Experimental Protocols for Assessing Clearance Pathways

Protocol 3.1: Pharmacokinetic and Biodistribution Study in Rodents

Objective: To quantitatively determine the plasma half-life, tissue distribution, and primary route of excretion of a novel NIR-II probe.

Materials: See "The Scientist's Toolkit" below.

Procedure:

• Animal Preparation: Use healthy, nude mice (n=5 per time point). Anesthetize and place on a heating pad.
• Probe Administration: Inject the NIR-II probe via tail vein at a standard dose (e.g., 100 µL of 100 µM solution).
• Serial Blood & Tissue Collection:
  • At pre-determined time points (e.g., 5 min, 30 min, 2h, 6h, 24h, 48h), collect blood retro-orbitally into heparinized tubes.
  • Immediately sacrifice animals at each time point. Harvest key organs: heart, liver, spleen, lung, kidney, muscle, tumor (if present), and intestine.
  • Collect urine and feces separately over 24h using metabolic cages for a separate cohort.
• Sample Processing & Quantification:
  • Centrifuge blood to obtain plasma.
  • Homogenize tissues in PBS (1:4 w/v).
  • Measure NIR-II fluorescence intensity in all samples (plasma, homogenates, excreta) using a calibrated NIR-II imaging system or spectrometer. Use a standard curve of the probe for concentration conversion.
• Data Analysis:
  • Plot plasma concentration vs. time. Calculate pharmacokinetic parameters (e.g., elimination half-life, AUC) using non-compartmental analysis software (e.g., Phoenix WinNonlin).
  • Express tissue data as % Injected Dose per Gram of tissue (%ID/g).
  • Determine primary excretion route by cumulative amount of fluorescence in urine vs. feces.

Protocol 3.2: Bile Duct Cannulation for Direct Assessment of Hepatobiliary Excretion

Objective: To provide definitive evidence of hepatic/biliary clearance.

Procedure:

• Surgical Preparation: Anesthetize a rat (preferred due to larger duct size) and secure it in a supine position. Maintain body temperature.
• Cannulation: Perform a midline laparotomy. Isolate the common bile duct. Cannulate it with PE-10 tubing, securing it with suture.
• Probe Administration & Bile Collection: Close the abdomen. Inject the NIR-II probe intravenously. Collect bile fractions continuously into pre-weighed tubes on ice for up to 6-8 hours.
• Analysis: Measure bile flow rate (by weight, assuming density=1 g/mL). Quantify probe concentration in each bile fraction and in concurrently collected plasma samples. A high bile-to-plasma ratio confirms active hepatobiliary excretion.

Protocol 3.3: Renal Clearance Mechanism Elucidation

Objective: To differentiate glomerular filtration from active tubular secretion/reabsorption.

Procedure:

• In Vivo Renal Function Pairing: Conduct Protocol 3.1 while simultaneously measuring the renal clearance of a known glomerular filtration marker (e.g., FITC-inulin).
• Calculation:
  • Clearance of Probe (CLprobe) = (Urine concentration * Urine flow rate) / Plasma concentration.
  • Clearance of Inulin (CLinulin) = GFR.
  • Filtration Fraction (FF) = CLprobe / CLinulin.
  • Interpretation: FF ≈ 1: Primarily filtered. FF > 1: Net tubular secretion. FF < 1: Net tubular reabsorption.
• In Vitro Cell Studies: Use cultured human proximal tubule cells (e.g., HK-2) to assess probe uptake/efflux, identifying potential transporter interactions (OAT, OCT, MDR) using specific inhibitors.

Visualization of Pathways and Workflows

Title: Decision Logic for NIR-II Probe Clearance Pathways

Title: Workflow for Clearance Pathway Determination

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for Clearance Pathway Studies

Item	Function & Relevance
NIR-II Fluorescence Imager	Core instrument for quantifying probe signal in vivo and ex vivo in the 1000-1700 nm range. Critical for biodistribution and PK analysis.
Calibrated NIR-II Fluorescence Standards	Essential for converting fluorescence intensity (counts) into quantitative concentration values for accurate PK modeling.
Metabolic Cages (Rodent)	Enables separate, quantitative collection of urine and feces over time for mass balance and excretion route studies.
Bile Duct Cannulation Kit	Surgical tools and polyethylene tubing for direct collection of bile, providing definitive proof of hepatobiliary excretion.
FITC-Inulin or Similar GFR Marker	A gold-standard tracer for measuring glomerular filtration rate (GFR). Used to normalize and understand renal clearance mechanisms.
Transporter-Expressing Cell Lines (e.g., MDCK-II-OAT1, HEK293-OCT2)	In vitro systems to identify specific renal or hepatic transporter interactions that mediate probe uptake/secretion.
Specific Transporter Inhibitors (e.g., Probenecid for OATs, Cimetidine for OCTs)	Pharmacological tools used in vitro and in vivo to block specific transporters, elucidating their role in probe handling.
Liquid Chromatography-Mass Spectrometry (LC-MS)	Gold-standard for quantifying parent probe and its metabolites in complex biological matrices (plasma, bile, urine), complementing fluorescence data.
Pharmacokinetic Analysis Software (e.g., Phoenix WinNonlin, PKSolver)	Software for modeling concentration-time data to calculate critical PK parameters (clearance, volume of distribution, half-life).

Within the development of NIR-II fluorescent probes for image-guided tumor surgery, achieving high tumor-to-background ratio (TBR) is paramount. A central challenge is the non-specific uptake of probes by the mononuclear phagocyte system (MPS), leading to sequestration in the liver and spleen, which obscures abdominal tumor margins and increases background signal. This application note details strategies and protocols to engineer probes for enhanced tumor specificity.

Key Strategies to Enhance Specificity

Strategies focus on modifying probe physicochemical properties and incorporating active targeting mechanisms.

1. Surface Engineering for Stealth Properties:

• Polyethylene Glycol (PEG) Conjugation: Creating a hydrophilic corona reduces opsonization and MPS recognition.
• Zwitterionic Coatings: Using materials like carboxybetaine provides superior anti-fouling properties compared to PEG.
• Biomimetic Camouflage: Coating with cell membranes (e.g., red blood cells, leukocytes) exploits natural biological functions to evade immune clearance.

2. Size and Charge Optimization:

• Size: Probes sized between 10-100 nm avoid rapid renal clearance and excessive liver sinusoid penetration.
• Charge: Neutral or slightly negative surfaces reduce non-specific interactions with negatively charged cell membranes.

3. Active Tumor Targeting:

• Ligand Conjugation: Attaching antibodies, peptides (e.g., RGD, cyclic RGD), or small molecules (e.g., folate) that bind to receptors overexpressed on tumor cells (e.g., αvβ3 integrin, folate receptor).

4. Responsive Activation:

• Designing probes that are optically silent until activated by the tumor microenvironment (TME), such as low pH, specific enzymes (e.g., MMP-2/9), or elevated glutathione.

Quantitative Comparison of Strategies

Table 1: Impact of Different Engineering Strategies on Probe Pharmacokinetics and Tumor Accumulation (Representative Data from Recent Studies).

Strategy	Probe Formulation	Hydrodynamic Size (nm)	Zeta Potential (mV)	Tumor AUC (0-24h) (%ID/g·h)	Liver Uptake at 24h (%ID/g)	Achieved TBR (NIR-II)
Baseline	Bare Ag2S QDs	12.5	-32.5	45.2	28.5	3.1
PEGylation	PEG5k-Ag2S QDs	21.8	-5.2	78.6	18.7	5.8
Zwitterionic	CB-Ag2S QDs	22.5	-1.8	85.4	12.3	8.2
Active Targeting	cRGD-PEG-Ag2S QDs	25.3	-6.5	112.7	17.1	9.5
Size Control	70nm DCNP-PLGA	71.4	-3.2	96.3	15.9	7.4

Abbreviations: QDs: Quantum Dots; DCNP: Doped Ceramic Nanoparticle; PLGA: Poly(lactic-co-glycolic acid); CB: Carboxybetaine; AUC: Area Under the Curve; %ID/g: Percentage of Injected Dose per gram of tissue.

Detailed Experimental Protocols

Protocol 1: Synthesis and Purification of cRGD-Conjugated, PEGylated NIR-II Probe

Objective: Prepare a actively targeted, stealth NIR-II probe (e.g., cRGD-PEG-IRDye1000CW analog). Materials: IRDye1000CW-COOH, NHS-PEG5k-Maleimide, c(RGDyK) peptide, DMSO, Phosphate Buffered Saline (PBS), PD-10 Desalting Column. Procedure:

• Activation: Dissolve 1 mg IRDye1000CW-COOH in 200 µL anhydrous DMSO. Add 5-fold molar excess of NHS-PEG5k-Maleimide and 10 µL triethylamine. React for 2 hours at room temperature (RT), protected from light.
• Conjugation: Add 10-fold molar excess of c(RGDyK) peptide (in PBS) to the reaction mixture. Adjust pH to 7.4. Allow conjugation to proceed overnight at 4°C.
• Purification: Load the reaction mixture onto a PD-10 column equilibrated with PBS. Elute with PBS and collect the first colored band.
• Characterization: Use UV-Vis-NIR spectroscopy to confirm conjugation (characteristic peaks at ~280 nm for peptide and ~1000 nm for dye). Measure size and charge via dynamic light scattering.

Protocol 2: In Vivo Validation of Tumor Specificity and Clearance

Objective: Quantify tumor uptake and liver/spleen sequestration in a murine xenograft model. Materials: Balb/c nude mice with subcutaneously implanted U87MG tumors (~200 mm³), probe solution (100 µM in PBS, 200 µL injection volume), NIR-II imaging system, analysis software (e.g., Living Image, Fiji). Procedure:

• Imaging: Anesthetize mouse with 2% isoflurane. Administer probe via tail vein injection. Acquire NIR-II images at 1, 4, 8, 12, and 24 hours post-injection using consistent parameters.
• Ex Vivo Analysis: At terminal time point (e.g., 24h), euthanize mouse, harvest tumor, liver, spleen, and key organs. Perform ex vivo NIR-II imaging.
• Quantification: Draw regions of interest (ROIs) around tumor and major organs. Calculate average radiant efficiency (p/s/cm²/sr) / (µW/cm²). Normalize to background. Report as %ID/g using a pre-established calibration curve.
• Data Calculation: Calculate TBR = (Signal Tumor / Signal Background Muscle). Calculate liver sequestration index = (Signal Liver at 24h / Signal Tumor at 24h).

Key Signaling Pathways and Workflows

Diagram Title: NIR-II Probe In Vivo Fate Pathways

Diagram Title: NIR-II Probe Specificity Assessment Workflow

The Scientist's Toolkit

Table 2: Key Research Reagent Solutions for NIR-II Probe Development.

Item	Function & Application in This Field
NIR-II Fluorophores (e.g., Ag2S/Ag2Se QDs, IRDye1000CW, CH1055, DCNPs)	Core imaging agent emitting in the NIR-II window (1000-1700 nm), providing deeper tissue penetration and reduced scattering.
Functional PEG Linkers (e.g., NHS-PEG-Mal, COOH-PEG-NHS)	Provides stealth properties, reduces MPS uptake, and offers chemical handles for conjugating targeting ligands.
Targeting Ligands (e.g., cRGD peptides, Trastuzumab fragments, Folic acid)	Mediates specific binding to biomarkers overexpressed on tumor cell surfaces or vasculature.
Zwitterionic Polymers (e.g., PCB, PSB)	Creates an ultra-low fouling surface on probes, significantly minimizing non-specific protein adsorption and cellular uptake.
Cell Membrane Vesicles (from RBCs, Platelets, Cancer cells)	For biomimetic coating, enabling prolonged circulation and homologous tumor targeting.
MMP-9/2 Cleavable Peptide Linker (e.g., PLGLAG)	Used to build protease-activated probes that switch on fluorescence specifically in the TME.
Dynamic Light Scattering (DLS) & Zeta Potential Analyzer	Essential instrument for characterizing hydrodynamic size, polydispersity index (PDI), and surface charge of nanoprobes.
Small Animal NIR-II Fluorescence Imager	In vivo imaging system equipped with InGaAs cameras for real-time, non-invasive tracking of probe distribution and tumor delineation.

Ensuring Batch-to-Batch Reproducibility and Scalable Synthesis for Clinical Translation

The clinical translation of NIR-II fluorescent probes for image-guided tumor surgery is predicated on the ability to manufacture probe material with consistent photophysical properties, biocompatibility, and targeting efficacy across multiple, scalable batches. Reproducibility challenges often arise from subtle variations in synthetic procedures, purification methods, and formulation steps. This application note provides detailed protocols and analytical frameworks designed to standardize the synthesis and characterization of NIR-II probes, such as those based on conjugated polymers, organic small molecules (e.g., donor-acceptor-donor structures), or inorganic nanoparticles (e.g., Ag₂S), to meet the stringent requirements for preclinical and clinical development.

Key Challenges in Reproducibility and Scale-Up

• Synthetic Heterogeneity: Minor fluctuations in reaction temperature, time, monomer purity, or catalyst activity can alter polymer chain length, molecular weight distribution, or nanoparticle size.
• Purification Inconsistency: Incomplete removal of precursors, catalysts, or by-products (e.g., unreacted dyes, ligands, metal ions) can affect probe fluorescence quantum yield, stability, and toxicity.
• Formulation Variability: Differences in nanoprecipitation, PEGylation, or surface functionalization protocols impact hydrodynamic size, zeta potential, and colloidal stability—critical parameters for pharmacokinetics and biodistribution.
• Analytical Gaps: Lack of rigorous in-process controls (IPCs) and release criteria for key attributes (e.g., NIR-II brightness, degree of labeling) leads to batch acceptance without objective metrics.

Standardized Synthesis Protocol: NIR-II Organic Dye-Polymer Conjugate

This protocol details the synthesis of a representative NIR-II probe: a PEGylated poly(maleic anhydride-alt-1-octadecene) (PMH) polymer conjugated with the NIR-II dye CH1055.

Materials: Research Reagent Solutions

Reagent/Material	Function/Justification
CH1055-COOH NIR-II Dye	Core fluorescent chromophore with carboxyl group for conjugation; emits in 1000-1400 nm range.
PEGylated PMH Polymer	Amphiphilic copolymer forms stable nanoparticles; PEG ensures stealth properties, anhydride allows amine coupling.
N,N'-Dicyclohexylcarbodiimide (DCC)	Carbodiimide coupling agent activates carboxyl groups.
N-Hydroxysuccinimide (NHS)	Enhances efficiency and stability of the activated ester intermediate.
Anhydrous Dimethylformamide (DMF)	Dry, aprotic solvent for conjugation reaction.
Triethylamine (TEA)	Base catalyst for the coupling reaction.
Dialysis Membranes (MWCO 3.5-10 kDa)	Purifies conjugate via size exclusion, removing small-molecule reactants and by-products.
Phosphate Buffered Saline (PBS), pH 7.4	Final formulation buffer for biological studies.
0.22 µm Sterile PVDF Syringe Filter	Sterile-filters final nanoparticle formulation.
Size Exclusion Chromatography (SEC) System	Analytical tool for monitoring conjugation efficiency and aggregation.

Detailed Conjugation and Nanoprecipitation Protocol

Aim: To reproducibly conjugate CH1055 dye to amine-functionalized PEG-PMH polymer and form stable, mono-disperse nanoparticles.

Procedure:

• Activation of Dye: In a flame-dried round-bottom flask under argon, dissolve CH1055-COOH (10.0 mg, 1.0 equiv) and NHS (2.2 equiv) in 5 mL anhydrous DMF. Cool to 0°C. Add DCC (2.5 equiv) in DMF dropwise. Stir at 0°C for 2 hours, then at room temperature (RT) for 4 hours. Monitor reaction by TLC or LC-MS.
• Precipitation of By-product: Cool the reaction mixture to 0°C for 1 hour to precipitate dicyclohexylurea (DCU). Filter through a 0.45 µm PTFE syringe filter into a clean vial. The filtrate contains the activated CH1055-NHS ester.
• Polymer Conjugation: To the stirred filtrate, add PEG-PMH-NH₂ polymer (100 mg, ensure molar ratio of dye: polymer anhydride units is ~1:50) and TEA (5 µL). Protect from light. Stir at RT for 24 hours.
• Purification: Transfer the reaction mixture to a dialysis membrane (MWCO 10 kDa). Dialyze against 4 L of DMF for 12 hours (change solvent once), followed by 4 L of deionized water for 48 hours (change every 8-12 hours) to remove all unreacted dye, DCU, and DMF.
• Nanoparticle Formation (Nanoprecipitation): Retrieve the dialyzed aqueous solution (concentrated conjugate). Using a syringe pump, add 5 mL of this solution dropwise (rate: 1 mL/min) into 20 mL of vigorously stirred PBS (pH 7.4). Stir for an additional 2 hours at RT.
• Final Processing: Filter the nanoparticle suspension through a 0.22 µm sterile PVDF filter. Aliquot and store at 4°C protected from light. Do not freeze.

Critical Process Parameters (CPPs) & In-Process Controls (IPCs)

CPP	Target Range	IPC Method	Consequence of Deviation
Reaction Humidity	<10% RH	In-line sensor	Hydrolysis of NHS ester reduces conjugation yield.
Dye:Polymer Ratio	1:50 (mol/mol)	Precise weighing	Affects fluorescence brightness and nanoparticle stability.
Dialysis Water Purity	18.2 MΩ·cm	Conductivity meter	Salt/impurity retention alters formulation buffer.
Nanoprecipitation Stir Rate	800 ± 50 rpm	Calibrated stirrer	Affects nanoparticle size and polydispersity.
Filtration Pressure	< 50 psi	Pressure gauge	High pressure may rupture nanoparticles.

Analytical Characterization for Batch Release

A standardized panel of assays must be performed on each batch prior to release for in vivo studies.

Table 1: Mandatory Batch Release Criteria for NIR-II Probes

Attribute	Target Specification	Analytical Method	Purpose
Hydrodynamic Diameter	30 ± 5 nm (PDI < 0.15)	Dynamic Light Scattering (DLS)	Ensures consistent biodistribution and renal clearance profile.
Zeta Potential	-20 to -30 mV (in PBS)	Electrophoretic Light Scattering	Predicts colloidal stability and non-specific cell interaction.
Absorption Max (λ_abs)	750 ± 10 nm	UV-Vis-NIR Spectroscopy	Confirms dye integrity and conjugate formation.
Emission Max (λ_em)	1050 ± 20 nm	NIR-II Spectrofluorometer	Verifies correct NIR-II emission window.
Fluorescence Quantum Yield (Φ)	≥ Batch #001 Reference -10%	Integrated sphere (using IR26 as reference)	Quantifies brightness consistency.
Degree of Labeling (DoL)	2.5 ± 0.5 dyes per polymer	UV-Vis/¹H NMR	Controls ligand density and fluorescence signal linearity.
Endotoxin Level	< 0.25 EU/mL	LAL Chromogenic Assay	Guarantees absence of pyrogenic contamination for in vivo use.
Sterility	No growth	USP <71>	Essential for survival surgery models.

Pathway to Scalable Synthesis

Moving from milligram (research) to gram (clinical) scale requires process adaptation.

Protocol for Scale-Up via Tangential Flow Filtration (TFF):

• After the conjugation reaction in DMF, dilute the mixture 5-fold with DI water.
• Circulate through a TFF system equipped with a 10 kDa MWCO polyethersulfone (PES) membrane.
• Perform diafiltration with 10 volume exchanges of DI water (constant volume). This replaces dialysis, reducing time from days to hours.
• Concentrate the retentate to the desired volume for nanoprecipitation.
• Scale nanoprecipitation by using a controlled chaotic mixer or multi-inlet vortex mixer for homogeneous supersaturation, ensuring batch size does not affect nanoparticle characteristics.

Visual Summaries

Title: NIR-II Probe Synthesis and QC Workflow

Title: Link Between CPPs, IPCs, and CQAs

Benchmarking NIR-II Probes: Preclinical Validation and Comparative Analysis with Clinical Standards

Within the broader thesis on developing next-generation NIR-II fluorescent probes for image-guided tumor surgery, a critical validation step involves benchmarking against established clinical standards. This document details the application notes and protocols for a comparative study evaluating a novel NIR-II probe against the clinically used NIR-I agent, Indocyanine Green (ICG), and the current histological gold standard, intraoperative frozen section analysis. The goal is to quantify the advantages of NIR-II imaging in terms of sensitivity, specificity, spatial resolution, and surgical workflow integration.

Quantitative Comparison Data

Table 1: Performance Metrics of NIR-I (ICG), NIR-II Probe, and Frozen Section Analysis

Metric	NIR-I Imaging (ICG)	NIR-II Imaging (Probe X)	Intraoperative Frozen Section
Optical Window	700-900 nm	1000-1700 nm	N/A (Histology)
Tissue Penetration Depth	~0.5-1 cm	~1-2 cm	N/A (Surface analysis)
Spatial Resolution (In Vivo)	~1-3 mm	~0.2-0.5 mm	~1-10 µm (cellular)
Tumor Detection Sensitivity	75-85%*	92-98%*	>95%
Tumor Detection Specificity	70-80%*	88-95%*	>97%
Turnaround Time	Real-time (~seconds)	Real-time (~seconds)	15-30 minutes
Primary Limitation	High background, low resolution	Probe availability/regulation	Sampling error, time lag

*Highly dependent on tumor type, dose, and imaging window.

Table 2: Comparative Analysis of Surgical Workflow Impact

Aspect	NIR-I/NIR-II Fluorescence Guidance	Frozen Section Analysis
Guidance Type	Continuous, wide-field	Discrete, point-sample
Information	Anatomic/functional (receptor expression)	Cytologic/architectural
Role in Decision	Guides resection boundaries	Confirms/refutes malignancy
Disruption to Surgery	Minimal	Moderate (pause for biopsy)

Experimental Protocols

Protocol 1: In Vivo Comparison of Tumor-to-Background Ratio (TBR)

• Objective: Quantify the signal clarity of NIR-II Probe X vs. ICG in a murine tumor model.
• Materials: See "The Scientist's Toolkit" below.
• Procedure:
  • Induce subcutaneous or orthotopic tumors in nude mice (e.g., U87MG glioblastoma).
  • At optimal tumor size, inject cohorts (n=5) intravenously with either ICG (0.1 mg/kg) or NIR-II Probe X (equimolar dose).
  • At the respective peak uptake time (e.g., 24h for Probe X, 5 min for ICG), anesthetize the animal.
  • Image sequentially using co-registered NIR-I (800 nm filter) and NIR-II (1550 nm filter) cameras in a multimodal imaging system.
  • Quantify mean fluorescence intensity (MFI) in the tumor region (ROIT) and in adjacent normal tissue (ROIN).
  • Calculate TBR = MFI(ROIT) / MFI(ROIN). Perform statistical analysis (Student's t-test).

Protocol 2: Correlation Study with Frozen Section Histology

• Objective: Validate fluorescence-positive margins against histological truth from frozen sections.
• Materials: Cryostat, OCT compound, H&E stain, fluorescence imaging system.
• Procedure:
  • Following in vivo imaging (Protocol 1), perform surgical resection of the tumor under fluorescence guidance.
  • Map and ink the surgical resection margin.
  • From the resected specimen, take thin tissue slices (~2-3 mm) from areas that were fluorescence-positive and fluorescence-negative at the margin.
  • Embed these slices in OCT, flash-freeze, and section at 5-10 µm using a cryostat.
  • Perform H&E staining on the frozen sections. A pathologist (blinded to fluorescence data) assesses for the presence of tumor cells.
  • Create a 2x2 contingency table to calculate sensitivity, specificity, PPV, and NPV of fluorescence imaging using frozen section as the reference standard.

Protocol 3: Protocol for Intraoperative Frozen Section Analysis (Reference Method)

• Objective: Generate a definitive histological diagnosis during surgery.
• Procedure:
  • The surgeon biopsies the tissue of concern and sends it fresh (unfixed) to the pathology lab.
  • The tissue is oriented on a cryostat chuck with OCT embedding medium and rapidly frozen to -20°C.
  • Thin sections (5-10 µm) are cut, mounted on slides, and fixed briefly.
  • Slides are stained with Hematoxylin and Eosin (H&E).
  • A pathologist examines the slides microscopically for tumor cells and relays the diagnosis (e.g., "positive margin," "benign tissue") to the operating room.

Visualization Diagrams

Diagram 1: Intraoperative Decision Workflow Integrating Fluorescence and Frozen Section

Diagram 2: Optical Principles Underlying NIR-II Superior Contrast

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 3: Key Reagents and Equipment for Comparative Studies

Item	Function/Benefit	Example/Note
NIR-II Fluorescent Probe	Target-specific (e.g., anti-EGFR) agent emitting >1000 nm for deep, high-contrast imaging.	CH1055 derivatives, semiconductor quantum dots, or organic dye-protein conjugates.
Indocyanine Green (ICG)	FDA-approved NIR-I dye for benchmark comparison; non-targeted perfusion agent.	Requires reconstitution; light and temperature-sensitive.
Multispectral NIR Imager	Imaging system capable of sequential or simultaneous acquisition in NIR-I and NIR-II windows.	Must have cooled InGaAs detectors for NIR-II; e.g., custom-built or commercial systems.
Cryostat	Microtome in a freezing chamber for producing thin frozen tissue sections for histology.	Essential for generating the frozen section gold-standard samples.
Animal Tumor Model	In vivo system for evaluating probe performance in a biologically relevant microenvironment.	Cell-line derived xenografts (CDX) or patient-derived xenografts (PDX) in immunocompromised mice.
Image Analysis Software	For quantifying Mean Fluorescence Intensity (MFI), drawing ROIs, and calculating TBR.	Open-source (ImageJ) or commercial (IVIS Living Image, MATLAB).
OCT Embedding Matrix	Water-soluble compound used to support tissue during frozen sectioning.	Maintains tissue architecture during rapid freezing.

In the development of NIR-II (1000-1700 nm) fluorescent probes for image-guided tumor surgery, objective and standardized quantitative metrics are critical for translating research from the bench to the operating room. These metrics enable the rigorous comparison of novel probes, optimization of imaging protocols, and the establishment of performance thresholds necessary for clinical adoption. Three pivotal metrics are the Contrast-to-Noise Ratio (CNR), which dictates intraoperative visualization quality; the Detection Limit, which defines the sensitivity for identifying microscopic residual disease; and the Tumor-to-Normal Tissue Ratio (TNR), which quantifies specific probe accumulation. This Application Note provides detailed protocols and context for measuring these parameters within a thesis framework focused on advancing NIR-II surgical imaging.

Table 1: Core Quantitative Metrics for NIR-II Fluorescent Probe Evaluation

Metric	Formula / Definition	Ideal Value (NIR-II Context)	Key Influencing Factors
Contrast-to-Noise Ratio (CNR)	CNR = |μ_t - μ_b| / σ_b μ=mean signal, t=tumor, b=background, σ=std dev of background	> 5 for robust visual discrimination in vivo	Probe brightness, imaging system noise, tissue autofluorescence, exposure time
Detection Limit	Minimum quantity of probe (e.g., picomoles) or number of labeled cells detectable above background with a SNR > 5.	Sub-nanomolar concentrations; < 1x10³ cells in vivo	Probe quantum yield, camera sensitivity, background tissue attenuation
Tumor-to-Normal Tissue Ratio (TNR)	TNR = Mean Signal_Tumor / Mean Signal_Normal Tissue (Normal tissue is often contralateral muscle or adjacent healthy parenchyma)	> 3 for useful surgical contrast; > 10 for high specificity	Probe pharmacokinetics, targeting specificity, clearance rate, time post-injection

Table 2: Representative Published Data for NIR-II Probes (Selected Examples)

Probe Name	CNR (in vivo)	Detection Limit (in vivo)	TNR (Peak, in vivo)	Key Reference (Year)
CH1055-PEG	~8.5 (at 24 h p.i.)	~3 nmol (phantom)	~4.5 (4 h p.i., U87MG)	Antaris et al., Nat. Mater. (2016)
LZ1105	>10 (real-time)	~0.5 mm tumor depth	>10 (2 h p.i., 4T1)	Li et al., Nat. Biomed. Eng. (2018)
FDA-approved ICG (in NIR-II)	~2-4	High µM range	~1.5-3	Zhu et al., Nat. Commun. (2019)
Aptamer-targeted Ag2S QD	N/A	1000 cells (subcutaneous)	~8.5 (3 h p.i., glioblastoma)	Zhang et al., Anal. Chem. (2020)

Detailed Experimental Protocols

Protocol 3.1: Measuring Contrast-to-Noise Ratio (CNR) in a Murine Subcutaneous Tumor Model

Objective: To quantitatively determine the visualization quality provided by an NIR-II probe in a live animal model.

Materials: See "The Scientist's Toolkit" (Section 5).

Procedure:

• Animal & Imaging Preparation:
  • Inoculate mice with tumor cells (e.g., 4T1, U87MG) subcutaneously. Proceed with imaging when tumors reach 50-100 mm³.
  • Administer the NIR-II probe via tail vein injection at the optimized dose (e.g., 100 µL of 100 µM solution).
  • Anesthetize the mouse at the predetermined peak imaging time post-injection (e.g., 6-24 h).

• Image Acquisition:

  • Place the animal in the NIR-II imaging system (e.g., custom setup with 808 nm or 980 nm laser excitation, 1000 nm long-pass emission filters, InGaAs camera).
  • Acquire an image sequence with appropriate exposure time (e.g., 100-500 ms) to avoid pixel saturation. Ensure identical imaging parameters for all animals in a cohort.

• Image Analysis (Using ImageJ/Fiji):

  • Region of Interest (ROI) Selection: Draw ROIs over: a) the entire tumor region (Tumor ROI), b) an adjacent background tissue region of equal area (Background ROI), typically muscle tissue near the tumor.
  • Data Extraction: Measure the mean signal intensity (μ_t, μ_b) and the standard deviation of the background ROI (σ_b).
  • Calculation: Compute CNR using the formula: CNR = |μ_t - μ_b| / σ_b.
  • Reporting: Report CNR as mean ± SD for an experimental group (n≥3). Include a representative image with ROIs overlaid.

Protocol 3.2: Determining In Vivo Detection Limit for Micrometastases or Residual Tumor Foci

Objective: To establish the smallest number of tumor cells or smallest tumor volume detectable with the NIR-II probe/imaging system.

Procedure:

• Model Establishment:
  • Cell-Derived Model: Create a dilution series of tumor cells (e.g., from 10⁶ down to 10 cells) labeled ex vivo with the probe or known to accumulate it. Inject these cells subcutaneously or into an organ (e.g., liver) in a controlled manner.
  • Surgical Residual Model: Perform a partial tumor resection in a mouse model, leaving behind a known, small remnant (e.g., < 1 mm³). Image the surgical bed.

• Image Acquisition & Analysis:

  • Image the animal using high-sensitivity settings (longer exposure, higher laser power within safety limits).
  • Define a Signal-to-Noise Ratio (SNR) threshold for "detection" (e.g., SNR > 5, where SNR = Mean Signal_Target / SD_Background).
  • The Detection Limit is defined as the smallest number of cells or tumor volume that consistently yields an SNR above this threshold in ≥90% of trials.

• Validation:

  • Correlate fluorescent findings with ex vivo histology (H&E staining) or immunohistochemistry to confirm the presence of tumor cells at the detected site.

Protocol 3.3: Calculating Tumor-to-Normal Tissue Ratio (TNR)

Objective: To quantify the specificity of probe accumulation in tumor versus healthy tissues.

Procedure:

• In Vivo Imaging & ROI Analysis:
  • Acquire in vivo images as per Protocol 3.1.
  • Draw ROIs over the entire tumor and over a contralateral or adjacent normal tissue of the same type (e.g., normal breast tissue for a mammary tumor, normal brain parenchyma for a glioma). Use consistent ROI sizes.
  • Calculate TNR_in vivo = Mean Signal_Tumor ROI / Mean Signal_Normal Tissue ROI.

• Ex Vivo Biodistribution Validation (Gold Standard):
  • At a terminal time point, euthanize the animal and harvest the tumor and major organs (heart, liver, spleen, lung, kidney, muscle, etc.).
  • Rinse tissues in PBS, image them ex vivo under the NIR-II system using standardized geometry.
  • Measure fluorescence intensity for each tissue sample.
  • Calculate TNR_ex vivo = Mean Signal_Tumor / Mean Signal_Specific Normal Tissue (often muscle is used as the reference normal tissue).
  • Weight Normalization: For quantitative biodistribution, homogenize tissues, extract the probe, and measure fluorescence with a calibrated spectrometer. Express data as % Injected Dose per Gram of tissue (%ID/g). TNR can then be calculated as (%ID/g)_Tumor / (%ID/g)_Normal Tissue.

Signaling Pathways & Experimental Workflows

Diagram 1: NIR-II Probe Evaluation Workflow

Diagram 2: Probe Targeting & Metric Relationship

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Probe Evaluation Experiments

Item / Reagent	Function & Role in Evaluation	Example Product / Specification
NIR-II Fluorescent Probe	The core agent enabling deep-tissue, high-resolution imaging.	E.g., CH1055-PEG, Ag2S Quantum Dots, LZ1105, or novel small-molecule dyes.
Near-Infrared Imaging System	Captures emission light in the 1000-1700 nm range.	Custom or commercial systems (e.g., InGaAs camera, 808/980 nm lasers, 1000 nm LP filters).
Calibration Phantoms	Provides standardized references for signal quantification and system performance checks.	Agarose or epoxy resin phantoms embedded with known concentrations of probe or reference dyes.
Image Analysis Software	Enables ROI-based quantification of signal intensity for CNR, TNR, and SNR calculation.	ImageJ/Fiji, LI-COR Image Studio, Living Image, or custom MATLAB/Python scripts.
Tumor Cell Lines	Used to establish in vivo models for probe evaluation.	Common lines: 4T1 (murine breast cancer), U87MG (human glioblastoma), CT26 (murine colon carcinoma).
Matrigel / Basement Membrane Matrix	Enhances tumor take rate when co-injected with cells for subcutaneous models.	Corning Matrigel, Growth Factor Reduced.
Isoflurane/Oxygen Anesthesia System	Maintains stable animal anesthesia during in vivo imaging sessions.	Precision vaporizer, induction chamber, nose cones.
Reference NIR Dye (e.g., ICG)	Serves as a benchmark for comparing the performance of novel NIR-II probes.	FDA-approved Indocyanine Green for NIR-I; can be used in NIR-II window with lower brightness.
Tissue Homogenization Kit	For ex vivo biodistribution studies to extract and quantify probe from organs.	Bead-based homogenizers (e.g., Bertin Instruments) in PBS or lysis buffer.

Within the broader thesis on developing next-generation NIR-II (1000-1700 nm) fluorescent probes for image-guided tumor surgery, a critical comparative analysis of four leading platforms is required. This analysis provides detailed application notes and experimental protocols to guide researchers in selecting and implementing the optimal probe for high-contrast, deep-tissue intraoperative imaging and margin delineation.

Quantitative Platform Comparison

Table 1: Core Photophysical & Performance Properties

Property	Organic Dyes (e.g., IR-1061)	Single-Walled Carbon Nanotubes (SWCNTs)	Quantum Dots (PbS/CdHgTe)	Rare-Earth Nanoparticles (REs, e.g., NaYF₄:Yb,Er)
Primary Emission Range (nm)	1000-1400	1000-1600	1000-1600	980, 1550 (upconversion also)
Quantum Yield (NIR-II, %)	0.1 - 0.5	0.1 - 1.0	5 - 20	0.1 - 10 (core-shell dependent)
Extinction Coefficient (M⁻¹cm⁻¹)	~10⁵	~10⁵ (per cm per mg/L)	10⁵ - 10⁶	~10⁴ (weak absorption)
Stokes Shift (nm)	Small (~10-30)	Very Large (>200)	Large (200-400)	Extremely Large (>300)
Photostability (t₁/₂ under laser)	Low (seconds-minutes)	Very High (hours)	High (minutes-hours)	Excellent (hours)
Typical Hydrodynamic Size	<2 nm	Length: 200-500 nm; Width: ~1 nm	5 - 15 nm	20 - 100 nm
Biodegradability	High	Low/Non-biodegradable	Low (heavy metal concerns)	Low (inorganic crystal)
Primary Renal Clearance	Yes (small)	No	No (large, RES uptake)	No (large, RES uptake)
Key Synthesis/Modification Challenge	Solubility, aggregation	Chirality separation, biocompatible coating	Heavy metal toxicity, reproducibility	Shell growth for brightness, size control

Table 2: In Vivo Surgical Imaging Performance Metrics

Metric	Organic Dyes	SWCNTs	Quantum Dots	Rare-Earth NPs
Tumor-to-Background Ratio (TBR) Peak	2 - 4	3 - 8	4 - 10	3 - 7
Signal-to-Noise Ratio (SNR)	Moderate	High	Very High	High
Optimal Imaging Depth (mm)	2-3	5-10	5-8	3-6
Blood Circulation Half-life (t₁/₂)	Minutes	Hours to days	Hours to days	Hours to days
Primary Targeting Strategy	Passive (EPR) & Active	Active (antibody conjugation)	Active (peptide/antibody)	Active (PEGylation + targeting)
Clinical Translation Barrier	Rapid clearance, low brightness	Long-term toxicity, batch variance	Heavy metal toxicity	Slow clearance, complex synthesis

Application Notes & Key Protocols

Protocol: Conjugation of Targeting Ligands to NIR-II Probes for Active Tumor Targeting

Objective: To functionalize the surface of each nanoparticle platform with cyclic RGD peptides for targeting αvβ3 integrin in tumor vasculature.

Materials:

• Probe: Carboxylated SWCNTs, PbS QDs, or NaYF₄:Yb,Er NPs (1 mg/mL in PBS, pH 7.4). For dyes, use NHS-ester derivative.
• Targeting Ligand: Cyclo(Arg-Gly-Asp-D-Phe-Cys) (cRGDfC) peptide.
• Crosslinkers: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS).
• Buffers: MES Buffer (0.1 M, pH 5.5), PBS (0.01 M, pH 7.4).

Procedure:

• Activation: For nanoparticles, mix 1 mL of probe solution with 2 mL MES buffer. Add 0.5 mg EDC and 1.2 mg NHS. React for 20 min at RT with gentle stirring.
• Purification: Purify activated NPs via centrifugation (14,000 rpm, 20 min) and resuspend in 2 mL PBS (pH 7.4).
• Conjugation: Add 2 mg of cRGDfC peptide to the activated probe solution. React for 4 hours at RT or overnight at 4°C.
• Quenching & Final Purification: Add 50 µL of 1 M glycine to quench the reaction. Stir for 15 min. Purify the conjugated probe via dialysis (MWCO 50kDa for NPs) or centrifugation against PBS for 48 hours. Sterilize via 0.22 µm filter. Store at 4°C.

Protocol: In Vivo NIR-II Image-Guided Tumor Resection in a Murine Model

Objective: To intraoperatively image and surgically resect a subcutaneous tumor using NIR-II fluorescence guidance.

Materials:

• Animal Model: BALB/c nude mouse with subcutaneously implanted U87MG tumor (~100 mm³).
• Imaging System: NIR-II fluorescence imaging system with 808 nm or 980 nm laser excitation and InGaAs camera.
• Anesthesia: Isoflurane vaporizer.
• Probe: cRGD-conjugated NIR-II probe (e.g., SWCNT or QD) at 2 nmol in 100 µL PBS.

Procedure:

• Pre-operative Baseline: Anesthetize mouse and acquire white-light and NIR-II background images.
• Probe Administration: Inject probe solution via tail vein.
• Intraoperative Imaging (at 24h post-injection): a. Anesthetize and secure mouse in supine position. b. Make a midline skin incision to expose the tumor area. c. Switch imaging system to NIR-II fluorescence channel. Use low laser power (~50 mW/cm²) to minimize photobleaching. d. Identify the primary tumor mass and any satellite micrometastases via fluorescence signal. Use real-time display to guide dissection.
• Fluorescence-Guided Resection: a. Using microsurgical tools, resect the primary fluorescent mass. b. Perform circumferential dissection, checking the resection bed with NIR-II imaging after each step. c. Resect any additional fluorescent foci suspected as metastases.
• Ex Vivo Validation: Image the resected tumor and the wound bed separately. Process tissues for histology (H&E) to confirm complete resection at margins.

Signaling Pathways & Experimental Workflows

The Scientist's Toolkit

Table 3: Essential Research Reagent Solutions for NIR-II IGS Probe Development

Item	Function & Rationale
Carboxylated Nanoparticles	Starting point for EDC/NHS chemistry; provides -COOH groups for stable amide bond formation with targeting ligands.
Heterobifunctional PEG Linkers (e.g., MAL-PEG-NHS)	Creates a hydrophilic stealth coating, reduces non-specific uptake, and provides functional end-groups for controlled conjugation.
cRGDfK or cRGDfC Peptides	High-affinity targeting ligands for αvβ3 integrin, overexpressed on tumor vasculature and many cancer cells.
EDC & NHS Crosslinking Kit	Standard carbodiimide chemistry for activating carboxyl groups to form reactive esters for peptide coupling.
Size-Exclusion Chromatography (SEC) Columns	Critical for purifying conjugated probes from unreacted small molecules, ensuring batch reproducibility and safety.
Dialysis Membranes (MWCO 50-100 kDa)	For buffer exchange and removal of excess salts/reactants post-conjugation, especially for nanoparticle platforms.
Sterile PBS (pH 7.4) & MES Buffer (pH 5.5)	PBS is the standard for final formulation and injection. MES provides optimal pH (~5.5) for efficient EDC-mediated activation.
0.22 µm Sterile Syringe Filters	Essential final step for aseptic preparation of injectable probe formulations for in vivo studies.
Matrigel Basement Membrane Matrix	For establishing consistent subcutaneous tumor xenografts when mixed with cancer cells.
Isoflurane & Veterinary Anesthesia System	Provides stable, reversible anesthesia for prolonged in vivo imaging and survival surgical procedures.

The development of NIR-II (1000-1700 nm) fluorescent probes for image-guided surgery demands preclinical validation in models that faithfully recapitulate human disease. Orthotopic models, where tumor cells are implanted into their native organ microenvironment, are superior to subcutaneous models for assessing probe performance. They enable realistic evaluation of surgical margins, micrometastasis detection, and therapeutic response due to their accurate pathophysiology, stromal interactions, and metastatic patterns. This document details protocols and considerations for using orthotopic models to validate the clinical utility of NIR-II probes.

Key Quantitative Comparisons of Preclinical Models

Table 1: Comparison of Preclinical Tumor Model Characteristics for NIR-II Probe Validation

Model Type	Anatomical & Stromal Relevance	Metastatic Potential	Suitability for Surgical Simulation	Throughput	Key Limitation for Imaging
Subcutaneous Xenograft	Low: Ectopic, lacks native microenvironment.	Very Low.	Poor: Non-anatomical location, no critical structures.	High: Easy to implant & monitor.	Minimal background/autofluorescence in NIR-II.
Orthotopic Xenograft	High: Correct organ anatomy & stroma.	Moderate to High: Organ-specific spread.	Excellent: Realistic margins & adjacent tissues.	Moderate: Requires specialized surgery.	Organ-specific autofluorescence & light scattering.
Patient-Derived Orthotopic Xenograft (PDOX)	Very High: Retains patient tumor histology.	High: Recapitulates clinical metastasis.	Excellent: Best for predictive validation.	Low: Technically challenging, expensive.	Variable probe uptake due to tumor heterogeneity.
Genetically Engineered Mouse Model (GEMM)	High: De novo, intact immune system.	High: Spontaneous, natural progression.	Good: Realistic micro-environment.	Low: Variable latency, cost.	Full immune system may clear probes faster.

Table 2: Metastatic Spread Patterns in Common Orthotopic Models

Primary Tumor Site (Cell Line Example)	Common Metastatic Sites (Validated by NIR-II Imaging)	Approximate Time to Metastasis (Post-Implantation)	Relevance to Clinical Surgery
Breast (4T1-Luc2, MDA-MB-231)	Lymph nodes, lungs, liver, bone.	3-4 weeks.	Detection of sentinel lymph node & distant micro-metastases.
Colon (CT26, HCT116)	Liver, peritoneal cavity, lymph nodes.	2-3 weeks.	Identification of hepatic & peritoneal metastases during resection.
Pancreas (Panc02, MIA PaCa-2)	Liver, peritoneum, local invasion.	4-5 weeks.	Delineation of locally invasive tumor margins.
Lung (LLC, A549-Luc)	Contralateral lung, mediastinal lymph nodes.	3-4 weeks.	Detection of satellite nodules and lymphatic spread.

Experimental Protocols

Protocol 3.1: Surgical Orthotopic Implantation of Breast Cancer Cells for Metastatic Model

Objective: To establish a primary tumor in the mouse mammary fat pad with subsequent spontaneous metastasis.

Materials:

• 6-8 week old female immunodeficient mice (e.g., BALB/c nude or NSG).
• 4T1-Luc2 or MDA-MB-231-Luc cells in log-phase growth.
• Matrigel, ice-cold.
• Sterile PBS.
• Anesthetic (e.g., isoflurane), analgesics.
• Surgical tools: fine scissors, forceps, wound clips.
• NIR-II imaging system.

Procedure:

• Cell Preparation: Harvest cells, resuspend in 50% PBS / 50% Matrigel on ice. Use 1x10^5 - 5x10^5 cells in 50 µL total volume per mouse.
• Anesthesia & Preparation: Anesthetize mouse and shave/clean the right lateral thoracic area. Perform all procedures aseptically.
• Incision: Make a 5-7 mm skin incision above the 4th mammary fat pad.
• Implantation: Expose the fat pad. Using a 27G insulin syringe, slowly inject the 50 µL cell suspension into the fat pad. Avoid leakage.
• Closure: Gently reposition the fat pad. Close the skin incision with wound clips.
• Post-op Care: Administer analgesia and monitor until recovery.
• Metastasis Monitoring: Allow primary tumor to grow for 3 weeks. Weekly, inject 3 mg/mL D-luciferin (i.p.) and perform bioluminescence imaging to monitor metastatic spread to lymph nodes, lungs, etc.

Protocol 3.2: NIR-II Probe Validation for Image-Guided Resection of Orthotopic Tumors

Objective: To assess the utility of a NIR-II probe in defining tumor margins and detecting micrometastases during simulated surgery.

Materials:

• Mice with established orthotopic primary tumors (from Protocol 3.1).
• NIR-II fluorescent probe (e.g., IRDye 800CW, CH-4T, or similar, functionalized for targeting).
• NIR-II fluorescence imaging system (equipped with 808 nm or 980 nm laser, >1000 nm emission filters).
• Surgical microscope adapted for NIR-II.

Procedure:

• Probe Administration: Inject the NIR-II probe intravenously at its optimized dose (e.g., 2 nmol in 100 µL PBS) and time window (e.g., 24 h pre-surgery).
• Pre-Resection Imaging: Anesthetize the mouse. Perform in vivo NIR-II imaging to locate the primary tumor and any fluorescent metastatic foci. Record signal-to-background ratios (SBR).
• Simulated Surgery: Make a standard surgical incision to expose the tumor site under white light.
• NIR-II Guided Resection: Switch to NIR-II imaging view. Use the real-time fluorescence guidance to identify tumor boundaries.
  • Attempt a "margin-negative" resection, leaving non-fluorescent tissue.
  • Identify and resect any fluorescent metastatic lymph nodes.
• Ex Vivo Validation: Image the resected tumor and suspected metastases. Image the resection cavity bed to check for residual fluorescence. Harvest all major organs for ex vivo NIR-II imaging to quantify undetected metastases.
• Histological Correlation: Fix tissues, section, and stain with H&E. Correlate fluorescence signals with histologically confirmed tumor cells to determine probe sensitivity and specificity.

Visualization: Pathways and Workflows

Title: Orthotopic Model NIR-II Probe Validation Workflow

Title: Metastatic Cascade & NIR-II Probe Targeting

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for Orthotopic Model Studies with NIR-II Imaging

Item	Function & Relevance	Example Product/Type
Immunodeficient Mice	Host for human or murine tumor cell lines without immune rejection. Essential for xenograft studies.	BALB/c nude, NOD-scid, NSG mice.
Matrigel / Basement Membrane Matrix	Provides a 3D support structure for implanted cells, improving orthotopic engraftment and growth.	Corning Matrigel, GFR.
Luciferase-Expressing Tumor Cells	Enables longitudinal tracking of tumor growth and metastasis via bioluminescence imaging (BLI).	4T1-Luc2, MDA-MB-231-Luc.
NIR-II Fluorescent Probe	The key agent for deep-tissue, high-resolution imaging and surgical guidance.	IRDye 800CW, CH-4T, Ag2S quantum dots, target-conjugated (e.g., anti-EGFR).
In Vivo Imaging System (IVIS)	Combines bioluminescence, NIR-I/II fluorescence for pre-operative metastasis mapping.	PerkinElmer IVIS Spectrum, LI-COR Pearl.
NIR-II Surgical Imaging System	Provides real-time intraoperative fluorescence guidance. Custom or adapted systems.	Modified Leica M-series microscopes with InGaAs cameras.
Tissue Clearing Agents	Renders tissues transparent for deep ex vivo 3D imaging of metastasis distribution.	CUBIC, iDISCO+.

1. Introduction & Thesis Context Within the broader thesis on developing novel NIR-II fluorescent probes for image-guided tumor surgery, the transition from preclinical research to clinical application necessitates rigorous regulatory planning. The Investigational New Drug (IND) application to the FDA (or equivalent to other agencies) is the critical gateway. This document outlines the specific IND-enabling studies and FIH trial design considerations for a hypothetical NIR-II fluorophore, "NIR-II-Guide-800," conjugated to a tumor-targeting moiety (e.g., an antibody fragment).

2. IND-Enabling Studies: A Structured Framework The primary goal is to demonstrate safety, biological activity, and a rationale for human testing. Studies must comply with Good Laboratory Practices (GLP).

Table 1: Core IND-Enabling Study Modules for NIR-II-Guide-800

Study Module	Primary Objectives	Key Endpoints (Quantitative)	Duration
Pharmacology	• Target binding affinity & specificity• Mechanism of tumor accumulation• Imaging efficacy in tumor models	• Kd (Dissociation constant): < 10 nM• Tumor-to-Background Ratio (TBR): > 5 at 24h post-injection• Signal Penetration Depth in tissue: > 8 mm	3-6 months
Toxicology (Core)	• Identify target organs of toxicity• Determine No Observed Adverse Effect Level (NOAEL)	• NOAEL: ≥ 10 mg/kg (single dose)• Maximum Tolerated Dose (MTD): 30 mg/kg• Clinical pathology markers within normal ranges	Up to 4 weeks
Toxicokinetics (TK)	• Relate exposure (dose) to toxicological findings	• Cmax (Peak plasma conc.): Dose-proportional• AUC (Area Under Curve): Linear from 1-30 mg/kg• Clearance half-life: ~12-18 hours (rodent)	Up to 4 weeks
Safety Pharmacology	• Assess effects on vital organ systems (CV, CNS, respiratory)	• No significant changes in ECG, blood pressure, respiratory rate	Single day
Synthesis & Chemistry	• Ensure consistent quality, purity, and stability	• Drug Substance Purity: ≥ 98%• Formulation Stability: ≥ 24 months at -20°C	Ongoing

3. Detailed Experimental Protocols

Protocol 3.1: In Vivo Toxicology & Toxicokinetics in Sprague-Dawley Rats (GLP)

• Test Article: NIR-II-Guide-800, formulated in sterile PBS.
• Animals: n=120 (10/sex/group for control, low, mid, high dose, plus TK satellite groups).
• Dosing: Single intravenous bolus via tail vein at 0 (vehicle), 10 (NOAEL target), 20, and 30 (MTD target) mg/kg.
• Observations: Twice-daily clinical observations; detailed physical exams weekly.
• TK Sampling: Serial blood draws from satellite groups at pre-dose, 5min, 30min, 2h, 8h, 24h, 48h, 72h post-dose. Analyze plasma via validated LC-MS/MS for fluorophore concentration.
• Necropsy & Histopathology: Full gross necropsy at terminal timepoints (24h and 28 days). Weigh and preserve ~40 tissues in formalin for H&E staining by board-certified pathologist.
• Data Analysis: Calculate standard TK parameters (Cmax, Tmax, AUC, t1/2) using non-compartmental methods. Correlate findings with histopathology results.

Protocol 3.2: Efficacy & Pharmacodynamics in Orthotopic Tumor Model

• Model: Nude mice with orthotopic human pancreatic cancer (MIA PaCa-2-Luc) implants.
• Imaging Agent: NIR-II-Guide-800 at 2 mg/kg (pharmacologic dose).
• Control: Untargeted NIR-II dye at same dose.
• Procedure:
  • Administer agent via tail vein injection (n=8/group).
  • Perform longitudinal NIR-II imaging at 1, 6, 24, 48, and 72h post-injection using a NIR-II imaging system (e.g., InGaAs camera, 1064nm excitation).
  • Quantify signal intensity in Tumor (T) and adjacent normal tissue (N) using region-of-interest (ROI) analysis.
  • Calculate TBR = Mean Tumor Signal / Mean Normal Tissue Signal.
  • Post-imaging, excise organs for ex vivo imaging to confirm biodistribution.
• Success Criteria: NIR-II-Guide-800 achieves a TBR > 5 at 24h, significantly higher than the untargeted control (p<0.01, Student's t-test).

4. First-in-Human (FIH) Trial Design The FIH trial for a diagnostic imaging agent is typically a Phase I, open-label, single ascending dose study in patients with the target tumor type.

Table 2: Proposed FIH Trial Design for NIR-II-Guide-800

Element	Design Specification
Title	Phase I, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Imaging Performance of NIR-II-Guide-800 in Patients with Solid Tumors.
Population	Patients with scheduled surgical resection of colorectal, pancreatic, or head & neck cancers (n=18-24).
Intervention	Single IV infusion of NIR-II-Guide-800.
Dose Escalation	3+3 design. Cohorts: 0.5 mg, 2 mg, 5 mg, 10 mg (or until MTD). Doses based on 1/10th rodent NOAEL (MRSD calculation).
Primary Endpoints	• Incidence of Adverse Events (Safety)• Maximum Tolerated Dose (MTD)
Secondary Endpoints	• Pharmacokinetics (Cmax, AUC, t1/2)• Tumor-to-Background Ratio (TBR) in surgical specimens via NIR-II imaging• Correlation of fluorescence with histopathological margins.
Imaging Protocol	Standard-of-care surgery performed 24h post-injection. Use an FDA-cleared NIR-II imaging system intraoperatively. Excised tumor is imaged ex vivo.

5. Visualization Diagrams

Title: Regulatory Path from Preclinical to FIH Trial

Title: FIH Trial 3+3 Dose Escalation Schema

6. The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Probe Development & Testing

Item / Reagent	Function / Purpose	Example Vendor/Product
NIR-II Fluorophore Core	The emitting molecule with excitation/emission >1000nm for deep tissue penetration and low autofluorescence.	Licor: IRDye QC-1; Sigma-Aldrich: Chromophore building blocks.
Tumor-Targeting Ligand	Provides specificity (e.g., antibody, peptide, small molecule) to accumulate the probe at the tumor site.	Creative Biolabs: Antibody fragment humanization & conjugation services.
Chemical Conjugation Kit	For stable, site-specific linking of fluorophore to targeting ligand (e.g., NHS ester, maleimide, click chemistry).	BroadPharm: SM(PEG)n crosslinkers; Thermo Fisher: Antibody Labeling Kits.
GLP-Test Article Formulation	Stable, sterile, endotoxin-free formulation for animal toxicology studies.	Charles River Laboratories: Formulation development & GMP manufacturing services.
NIR-II In Vivo Imaging System	For non-invasive, longitudinal imaging of probe biodistribution and tumor targeting in preclinical models.	Suzhou NIR-Optics: NIRvana系列; InnoSpectra: NIR-II Imaging Systems.
Validated Bioanalytical Assay (LC-MS/MS)	To quantify probe concentration in biological matrices (plasma, tissue) for pharmacokinetic/toxicokinetic analysis.	Covance/Labcorp: GLP-compliant assay development and validation.

Conclusion

NIR-II fluorescence imaging represents a paradigm shift in intraoperative visualization, offering unprecedented capabilities for precise tumor margin identification and vital structure preservation. The foundational optical advantages of the NIR-II window provide a compelling physical rationale, which is now being realized through sophisticated probe methodologies spanning small molecules to nanomaterials. Successful clinical translation, however, hinges on systematically overcoming optimization challenges related to brightness, specificity, and safety—areas where focused research is yielding promising solutions. Validation studies consistently demonstrate the superior performance of optimized NIR-II probes against current clinical standards like ICG. The future direction involves the convergence of smarter, activatable probes with multimodal imaging systems and AI-enhanced surgical navigation. For researchers and drug developers, the path forward requires a multidisciplinary approach that balances innovative chemistry with rigorous preclinical validation, ultimately paving the way for NIR-II imaging to become a standard-of-care tool in oncological surgery, improving patient outcomes through significantly more complete tumor resections.